{
  "doc_id": "legal-advice_43",
  "category": "legal-advice",
  "chunks": [
    {
      "id": "legal-advice_43__0",
      "chunk_id": "0",
      "content": "Office of Chief Counsel\nInternal Revenue Service Memorandum\nRelease Number: 20114901F\nRelease Date: 12/9/2011\nCC:LB&I:RFPH:MAGilbert\nPOSTU 139175-10\nUILC: 162.25-04, 174.06-00, 263.12-01, 263.13-00, 1253.01-00 date: September 14, 2011 to: from: subject: Technical Advisor\n(Pharmaceuticals and Biotech)\nIndustry Counsel (Pharmaceuticals and Biotech)\nLarge Business & International Attorney Fees Incurred to Defend Against Patent Infringement Claims and to\nInvestigate Patents This memorandum responds to your request for assistance. This advice may not be\nused or cited as precedent. LEGEND\nCorporation X\nCorporation Y\nCorporation Z\nEntity Y\nEntity Z\nANDA One\nANDA Two\nANDA Three\nLicense Y\nLicense Z\nDrug #1\nDrug #2\nDrug #3\nDrug #4\nIDR #1 = ---------------------------------------------------------------------------------------------------= ------------------------------------------------= ------------------------------------------= -------------------------------------------= ------------------------------------------------------= -----------------------= -----------------------= -----------------------= ------------------------------------------------= ------------------------------------------------= --------------------------------------------------------= --------------------------------------------------------= -----------= -----= ---------------- POSTU-139175-10\nIDR #2 2\n= ---------------- ISSUES\n1. Whether attorney fees must be capitalized pursuant to I. R.C. § 263 when\nincurred to defend actions for patent infringement pursuant to 35 U.S.C.\n§ 271(e)(2) for filing Abbreviated New Drug Applications (ANDAs) with the\nFood and Drug Administration (FDA) to obtain FDA approval to\ncommercialize generic drugs before the expiration of the listed patents. 2. Whether attorney fees must be capitalized pursuant to I.R.C. § 263 when\nincurred for investigatory patent research relative to certifications to the FDA\non the scope and validity of the patents in ANDAs with paragraph IV\ncertifications. CONCLUSIONS 1. The attorney fees incurred to defend actions for patent infringement pursuant\nto 35 U.S.C. § 271(e)(2) for submitting ANDAs to market and sell generic\ndrugs before the expirations of the listed patents must be capitalized. 2. The attorney fees incurred for investigatory patent research relative to filing\nANDAs before the expiration of the patents must be capitalized. The questions posed with respect to cost recovery of the capitalized attorney fees will\nbe addressed in a separate memorandum. FACTS -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1\n1 ------------------------------------------------------------------------------------------------------------------------------------------ POSTU-139175-10 3 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------2. -------------------------------------------------------------------------------------------------------------------------------------------------3. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------; POSTU-139175-10 4 2. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------2--------------------------------------------------------------------3. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------3 -------------------------------------------------------------------------------------------4 -----------------------------------------5 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------,6 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. 2. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------a. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- b. ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- 2 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 3 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 4 --------------------------------------------------------------------- 5 -------------------------------------------------------------------------------------------------------------------------------------------------------- 6 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 3. 5 a. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(1) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(2) ------------------------------------------------------------------------------------------------------------------------- b. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(1) -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(2) ------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------a. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(1) ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(2) ------------------------------------------------------------------------------------------------------------------------- b. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(1) --------------------------------------------------------------------------------------------(2) ------------------------------------------------------------------------------------------------------------------------- c. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ POSTU-139175-10\n(1) (2) 6\n-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------7 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------8 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------9 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------10 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------7 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 8 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 9 ------------------------------------------------------------------------------------------------------------------------------------------------------- 10 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 7 ------------------------------------------------------------------------------------------------------------------------------------11 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------11 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 8 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------12 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• -------------------------------------------------------------------------------------------------------------- • -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------12 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 9 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 2. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 10 3. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 4. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. ------------------------------------------------------------------------------------------------------------------------------------------- 2. ------------------------------------------------------------------------------------------------------------------------------------------------------------- 3. --------------------------------------------------------------------------------------------------------------------------------------------------------------------- 4. -------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 11 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------13 --------------------------------------------------------------- 13 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• • ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 12 -------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------• -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 13 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 14 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 15 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(a) -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(b) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- (c) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ (d) ------------------------------------------------------------------------------------------------------------------------------ POSTU-139175-10\n(e) 16 ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 17 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ POSTU-139175-10 18 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ POSTU-139175-10 19 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 20 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------14 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------14 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 21 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------2. -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------3. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------4. ---------------------------------------------------------------------------------------------------------------------------------5. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 22 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 23 2. ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 3. ------------------------------------------------------------------------------------------------------------------------------------------------------- 4. -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(a) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(b) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- (c) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 24 (d) -------------------------------------------------------------------------- (e) -------------------------------------------------------------------------- (f) -------------------------------------------------------------------------- (g) ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- (h) ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 25 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 26 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 27 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Legal Fees Incurred --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Corporation X’s Position\nCorporation X asserts all litigation fees are deductible as ordinary business\nexpenditures under IRC."
    },
    {
      "id": "legal-advice_43__1",
      "chunk_id": "1",
      "content": "----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 3. ------------------------------------------------------------------------------------------------------------------------------------------------------- 4. -------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(a) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------(b) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- (c) --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 24 (d) -------------------------------------------------------------------------- (e) -------------------------------------------------------------------------- (f) -------------------------------------------------------------------------- (g) ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- (h) ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 25 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 26 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 27 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Legal Fees Incurred --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Corporation X’s Position\nCorporation X asserts all litigation fees are deductible as ordinary business\nexpenditures under IRC. § 162, with Treas. Reg. §1.263(a)-4(d)(9) not applicable\nbecause “Corporation X did not hold, nor was it seeking title to [,] any intangible as part\nof the litigation process.“ Corporation X’s Response to Question 1, IDR #1. POSTU-139175-10 28 Corporation X further asserts15 (footnotes in original, renumbered to be\nconsecutive within this document): The legal expenses and costs of defending a lawsuit can be\ndeducted by a corporation conducting a trade or business if the suit\narises in the ordinary course of the business. 16 In Industrial\nAggregate, the taxpayer-lessee was sued by its landlord for\nallegedly violating terms of the operating covenants. The U.S.\nCourt of Appeals ruled that although the suit involved the taxpayer's\ntitle to a lease extension, the primary purpose of the suit was to\ncollect damages for that taxpayer's alleged violation of the\noperating covenants of the lease. As such, the professional fees\nincurred in the suit were deductible. In Corporation X’s case, the\nprimary purpose of Corporation Y’s lawsuit was to attempt to\ndefend its own exclusivity over the Drug #1 and Drug #2 products. As the primary purpose of the suit surrounded the validity of\nCorporation Y’s exclusivity, the professional fees incurred by\nCorporation X to defend against this exclusivity should not fall\nunder the purview of §1.263(a)-4(d)(9). Lawsuits brought about by the brand Company are a regular\noccurrence in the pharmaceutical industry, and as such, the\nprofessional fees related to this litigation should be deductible. In\nUrquahart [sic] v. Commissioner17, the Court held that the legal\nexpenses incurred in an infringement litigation suit were directly\nconnected to and ‘peculiarly normal’ to the taxpayer's business and\nwere therefore deductible. In its litigation with Corporation Y,\nCorporation X was neither seeking to create or acquire an\nintangible, but rather was attempting to demonstrate that it had not\ninfringed in any of the brand company’s patents. Generally, an expenditure must be \"directly connected\" with, have\n\"proximately resulted from,\" the taxpayer's trade or business activity\nin order to be deductible under § 162. The Supreme Court first\nconsidered the causation question in Kornhauser v. U.S., 276 U.S.\n145 (1928) which involved the deductibility of legal and accounting\nfees incurred by the taxpayer in defending against a suit brought by\nthe taxpayer’s former partner after the partnership dissolved. The\n15 While Corporation X’s position is stated with respect to the Corporation Y litigation, it is understood that\nthe position applies to all legal fees the subject of this advice. 16 “See e.g. Industrial Aggregate Co. v. US, 284 F.2d 639 (8th Cir. 1960) (fees paid in defense of action\nby taxpayer's landlord alleging breach of operating covenants of four leases were deductible because\nthey arose in ordinary course of business).” (id., quoting n.1)\n17 “Urquahart [sic] v. Commissioner, 215 F. 2d 17 (3d Cir. 1954).” (id., quoting n.2) POSTU-139175-10 29"
    },
    {
      "id": "legal-advice_43__2",
      "chunk_id": "2",
      "content": "“Urquahart [sic] v. Commissioner, 215 F. 2d 17 (3d Cir. 1954).” (id., quoting n.2) POSTU-139175-10 29 Supreme Court held that it did not matter that the suit was not\nbrought until after the partnership had terminated; the suit was still\n\"directly connected with\" or “proximately resulted from\" the\nbusiness. Therefore, the attorneys' fees in question were currently\ndeductible. In Corporation X's case, the professional fees incurred\nwith respect to the Corporation Y lawsuit were directly tied to\nCorporation X’s core business. The Company's ability to defend its\nposition that it is not infringing on existing patents is part of its\nnormal course of business, and as such, the expenditures shall be\ndeductible under IRC §162 (a). Corporation X’s Response to IDR #1 (emphasis added). In its response to Question 1, IDR #2, Corporation X stated that the litigation fees were\n“costs primarily associated with litigation to protect profits Corporation X would receive\nfrom the sales of the future products.” (emphasis added) Corporation X stated relative\nto the Development/Pre-filing Investigation fees that “[t]his category represents costs for\nthe pre-filing research and documentation of non-infringement positions with respect to\nthe formulation of the drugs that the Company was developing and does not contribute\nto the ANDA being filed.” Corporation X did not provide any other facts relative to these\nfees. Corporation X has not raised any other arguments to support deducting, rather\nthan capitalizing, the attorney fees. LAW AND ANALYSIS\nI.R.C. § 263(a) generally prohibits deductions for capital expenditures, with deductions\nthe exception to the norm of capitalization. The norm of capitalization was explained in\nIndopco v. Commissioner, 503 U.S. 79 (1992), as follows: In exploring the relationship between deductions and capital\nexpenditures, this Court has noted the “familiar rule” that “an\nincome tax deduction is a matter of legislative grace and that the\nburden of clearly showing the right to the claimed deduction is on\nthe taxpayer.” The notion that deductions are exceptions to the\nnorm of capitalization finds support in various aspects of the Code. Deductions are specifically enumerated and thus are subject to\ndisallowance in favor of capitalization. See §§ 161 and 261. Nondeductible capital expenditures, by contrast, are not\nexhaustively enumerated in the Code; rather than providing a\n“complete list of nondeductible expenditures,” § 263 serves as a\ngeneral means of distinguishing capital expenditures from current\nexpenses. 503 U.S. at 84 (1992) (citations omitted, emphasis added). POSTU-139175-10 30 The Indopco Court, in holding the expenditure at issue was not deductible, rejected the\nargument that the expenditure could be deducted because it did not create or enhance\na separate asset, clarifying its opinion in Commissioner v. Lincoln Savings & Loan\nAss’n, 403 U.S. 345 (1971), as follows:\nNor does our statement in Lincoln Savings that “the presence of an\nensuing benefit that may have some future aspect is not\ncontrolling” prohibit reliance on future benefit as a means of\ndistinguishing an ordinary business expense from a capital\nexpenditure. Although the mere presence of an incidental future\nbenefit - “some future aspect” - may not warrant capitalization, a\ntaxpayer's realization of benefits beyond the year in which the\nexpenditure is incurred is undeniably important in determining\nwhether the appropriate tax treatment is immediate deduction or\ncapitalization."
    },
    {
      "id": "legal-advice_43__3",
      "chunk_id": "3",
      "content": "Although the mere presence of an incidental future\nbenefit - “some future aspect” - may not warrant capitalization, a\ntaxpayer's realization of benefits beyond the year in which the\nexpenditure is incurred is undeniably important in determining\nwhether the appropriate tax treatment is immediate deduction or\ncapitalization. Indopco, 503 U.S. at 87 (citations and footnote omitted)(emphasis added). Accordingly, based on general capitalization principles articulated in Lincoln Savings\nand Indopco, an expenditure that creates or enhances a separate and distinct asset is\ncapitalizable, but the expenditure may still be capitalizable even if it does not create or\nenhance a separate and distinct asset. Determining whether the expenditures at issue must be capitalized as within I.R.C.\n§ 263 (rather than deducted under § 16218 or excluded from capitalization under I.R.C.\n§ 17419) requires a two step analysis. In the first step, addressed in Section I, below,\n18 I.R.C. § 162(a) allows a deduction for ordinary and necessary expenses paid or incurred during a\ntaxable year in carrying on a trade or business. “To qualify as an allowable deduction under § 162(a), an\nitem must be: (1) ‘be paid or incurred during the taxable year’; (2) be for ‘carrying on any trade or\nbusiness’; (3) be an ‘expense’; (4) be a ‘necessary’ expense; and (5) be an ‘ordinary expense’. Commissioner v. Lincoln Savings & Loan Ass’n, 403 U.S. 345, 352 (1971) (citations omitted). However,\nthe Lincoln Savings Court cautioned that “[i]t is not enough, in order that an expenditure qualify as an\nincome tax deduction, that it merely be . . . paid by all similarly [situated taxpayers], or that it serves to\nfortify . . . purpose and operation.” 403 U.S. at 354. The Court then held that the expenditure at issue\nwas not deductible as an ordinary and necessary business expense because it created or enhanced an\n“additional asset and that, as an inevitable consequence, the payment is capital in nature.” 403 U.S. at\n354 (emphasis added). 19 Expenditures within the twelve code sections listed in I.R.C. § 263(a)(1) are not within the mandate of\ncapitalization in I.R.C. § 263(a), with one of the listed code sections I.R.C. § 174. The fees at issue are\nnot within § 174 because the fees were incurred to acquire the right to market and sell Corporation X’s\ngeneric drugs prior to the expiration of the patents on the branded drugs the generic drugs “mimic.” The\nsubstantial fees incurred to prepare for a paragraph IV certification (paragraph IV certifications are\nexplained in Addendum A) and to defend the paragraph IV certification in infringement litigation in order to\nexpedite commercialization of the already developed generic drugs are not minor costs incurred in\n“connection with inventions or improvements from research and development in the experimental or\nlaboratory sense undertaken directly by the taxpayer or carried on in his behalf by another person or\norganization,” as required to be within § 174. Rev. Rul. 66-30, 1966-1 CB 55, applying Treas. Reg. §\n1.174-2. None of the fees at issue were incurred in obtaining a patent for any research and development POSTU-139175-10 31 the origin of the claim test must be applied, considering the relevant facts and\ncircumstances."
    },
    {
      "id": "legal-advice_43__4",
      "chunk_id": "4",
      "content": "Rev. Rul. 66-30, 1966-1 CB 55, applying Treas. Reg. §\n1.174-2. None of the fees at issue were incurred in obtaining a patent for any research and development POSTU-139175-10 31 the origin of the claim test must be applied, considering the relevant facts and\ncircumstances. A key fact is that the attorney fees at issue were incurred to obtain the\nright to market and sell new generic drugs in the United States. An overview of the\nstatutes, regulations, and case law that governs obtaining the right to market and sell\nnew generic drugs in the United States is set forth in Addendum A, attached hereto and\nincorporated herein. In the second step, addressed in Section II, below, whether the\nfees are within § 263 must be analyzed, specifically considering the 2004 capitalization\nof intangibles regulations. 20\nSection I. Origin of the Claim The characterization of the attorney fees at issue as deductible expenses within I.R.C.\n§ 162 or as capital expenditures within I.R.C. § 263 must first be analyzed using the\norigin of the claim test. United States v. Gilmore, 372 U.S. 39, 49 (1963)(“the origin and\ncharacter of the claim with respect to which an expense was incurred, rather than its\npotential consequences upon the fortunes of the taxpayer, is the controlling basic test of\nwhether the expense . . . is deductible or not. . .”). See Deputy v. DuPont, 308 U.S.\n488, 494 (1940) (“It is the origin of the liability out of which the expense accrues which\nis material.”) In Woodward v. Commissioner, 397 U.S. 572 (1970), the Supreme Court explained\nthat:\nA standard based on the origin of the claim litigated comports with\nthis Court's recent ruling on the characterization of litigation\nexpenses for tax purposes in United States v. Gilmore, 372 U.S.\n39, 83 . . . (1963). This court there held that the expense of\npreviously undertaken to develop the generic drugs and/or to establish their bioequivalence with the\nbranded drugs, so none of the fees are within Treas. Reg. § 1.174-2(a)(1). See Rev. Rul. 67-401, 1967-2\nC.B. 123 (“The expenses for legal and accounting work incurred by the taxpayer in applying for a Federal\nincome tax ruling in connection with a research and development project and a determination of a\nregulatory commission with respect to the effect of the project on the taxpayer’s rate structure are not\ndeductible as research and experimental expenditures under section 174(a) of [the Code]”). At no time\nhas Corporation X contended the fees addressed herein are within § 174. 20 Due to the “difficulty of translating general capitalization principles into clear, consistent and\nadministrative standards,” the capitalization of intangibles regulations were drafted because “much of the\nuncertainty and controversy *** has related to expenditures that create or enhance intangible assets or\nbenefits.” Announcement 2002-9, 2002-1 C.B. 536. To reduce this uncertainty and controversy, for a\nspecifically delineated subset of expenditures (i.e., expenditures not within the scope of the intangible\nregulations), capitalization will not be proposed solely on the grounds that the intangible asset has a\nsignificant future benefit until further guidance is published. 2004-1 C.B. 447, T.D. 9107, § II.A., General\nPrinciple of Capitalization."
    },
    {
      "id": "legal-advice_43__5",
      "chunk_id": "5",
      "content": "2004-1 C.B. 447, T.D. 9107, § II.A., General\nPrinciple of Capitalization. The regulations did not reverse the norm of capitalization; the subset of\nexpenditures that are not within the regulations is limited given the breadth and depth of the regulations. Moreover, the preamble to the 2004 capitalization of intangible regulations clearly states that “[t]he IRS\nand Treasury Department intend to construe broadly the categories of intangibles identified in the\nregulations in response to any narrow technical arguments that an intangible created by the taxpayer is\nnot literally described in the categories.“ T.D. 9107, 2004-1 C.B. 447 § II. D. Created Intangibles. POSTU-139175-10 32 defending a divorce suit was a nondeductible personal expense,\neven though the outcome of the divorce case would affect the\ntaxpayer's property holdings, and might affect his business\nreputation. The Court rejected a test that looked to the\nconsequences of the litigation, and did not even consider the\ntaxpayer's motives or purposes in undertaking defense of the\nlitigation, but rather examined the origin and character of the claim\nagainst the taxpayer, and found that the claim arose out of the\npersonal relationship of marriage. 397 U.S. at 578 (1970) (emphasis added). In accord, United States v. Hilton Hotels Corp., 397 U.S. 580, 583 (1970) (“As we held\nin Woodward, supra, the expenses of litigation that arise out of the acquisition of a\ncapital asset are capital expenses, quite apart from whether the taxpayer’s purpose in\nincurring them is the defense or perfection of title to property.”); McKeague v. United\nStates, 12 Cl. Ct. 671, 675 (1987) aff’d without published opinion, 852 F.2d 1294 (Fed.\nCir. 1988) (the objective in the origin of the claim test is “to find the transaction or\nactivity from which the taxable event approximately resulted”); American Stores v.\nCommissioner, 114 T.C. 458, 470 (2000)(reiterates that the primary purpose test has\nbeen rejected, and states the “nature of the transaction out of which the expenditure in\ncontroversy arose governs … regardless of the motives”); Anchor Coupling v. United\nStates, 427 F.2d 429, 434 (7th Cir. 1970)(rejected primary purpose test in favor of the\norigin of the claim test for settlements); Keller Street Development Company v.\nCommissioner, 688 F. 2d 675, 678, 680 (9th Cir. 1982)(the origin of the claim is not\n“based on the consequences to the taxpayer” and does not look to the primary\npurpose). In general, the above cases establish that, in applying the origin of the claim test, the\npurpose, consequence, or result is irrelevant. The origin of the claim test is an objective\ninquiry to determine the origin and character of the claim from which the litigation\nproximately resulted, taking into account all of the facts and circumstances; it is not a\ntest dependent on the formal titles to pleadings or subjective motives. The intangible\nregulations, Treas. Reg. §1.263(a)-4, also provide that determinations of whether to\ncapitalize should be made taking into account all of the facts and circumstances,\ndisregarding distinctions between labels. Treas. Reg. §1.263(a)-4(d)(1). A. Applying the Origin of the Claim Test to the Facts Before the infringement suits at issue were filed, Corporation X notified21 the New Drug\nApplication (NDA) holders22 for the referenced drugs23 and the patentees for the listed\n21"
    },
    {
      "id": "legal-advice_43__6",
      "chunk_id": "6",
      "content": "Treas. Reg. §1.263(a)-4(d)(1). A. Applying the Origin of the Claim Test to the Facts Before the infringement suits at issue were filed, Corporation X notified21 the New Drug\nApplication (NDA) holders22 for the referenced drugs23 and the patentees for the listed\n21 Notifications are required by law, as explained in Addendum A, which summarizes the statutory and\nregulatory regime governing the marketing and selling of new drugs in the United States. POSTU-139175-10 33 patents24 that Corporation X had filed applications with the Federal Food and Drug\nAdministration (FDA) to obtain the right to market and sell its new generic drugs before\nthe expiration of their listed patents. 25 The notifications specifically stated Corporation X\nhad filed Abbreviated New Drug Applications (ANDAs) with paragraph IV\ncertifications,26 certifying that the listed patents were either invalid or not infringed by\nCorporation X’s new generic drugs. To support its good faith in certifying that the\npatents were invalid or not infringed, Corporation X paid patent attorneys to research\nthe listed patents for the referenced drugs. For each drug, in each notification letter, Corporation X detailed its grounds for\ncontending the listed patents were not infringed. Additionally, in each notification letter,\nCorporation X specifically reserved the right to assert the patents were invalid if the\nNDA holders or patentees brought infringement suits. Each lawsuit filed against\nCorporation X was filed within 45 days of receiving Corporation X’s notification letters,\nthe time period for commencing suit for the NDA holders to obtain a 30-month stay. The stay precludes the FDA from approving Corporation X’s ANDAs for 30 months\nunless Corporation X prevails in the infringement litigation. On an ANDA-by-ANDA\nbasis, if no infringement suits had been filed within the 45 day window, subject to\nconfirming bioequivalence,27 the FDA could have immediately approved Corporation X’s\nANDAs. Each law suit asserted infringement pursuant to 35 U.S.C. § 271(e)(2). As explained\nfurther in Addendum A, 35 U.S.C. § 271(e)(2) creates an artificial act of infringement,\nmaking the filing of an ANDA with a paragraph IV certification an act of infringement. Each and every claim of infringement in the law suits at issue relied upon 35 U.S.C.\n§ 271(e)(2) for the asserted acts of infringement. An infringement claim based on 35\nU.S.C. § 271(e) has limited remedies, which do not include an award of lost profits. See Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661, 676 (1990) (‘The remedies\nprescribed by [35 U.S.C. §271(e)(4)] subparagraphs (A), (B), and (C) are the only\nremedies which may be granted by a court for an act of infringement described in 22 The term “NDA holders” is explained in Addendum A. 23 The term “referenced drug” is defined and explained in Addendum A. 24 The term “listed patents” is defined and explained in Addendum A. 25 It is noted that Corporation X could have waited until the patents expired since, as explained in\nAddendum A, there are four different types of certifications to seek approval to market and sell generic\ndrugs in the United States, with only a paragraph IV certification a direct challenge to the validity or scope\nof the listed patents for the referenced drugs."
    },
    {
      "id": "legal-advice_43__7",
      "chunk_id": "7",
      "content": "See 21 USC § 355 (j)(2)(A)(vii)(2010) (quoted in\nAddendum A). 26 The term “paragraph IV certification” is further explained in Addendum A. 27 The term “bioequivalence” is defined in Addendum A. POSTU-139175-10 34 paragraph 2, except that a court may award attorney fees under [35 U.S.C.] section\n285.”). 28 Thus, other than an award of fees and costs pursuant to 35 U.S.C. § 285 for an\nexceptional case (e.g., frivolous paragraph IV certification or trial misconduct),29 the\npotential statutory remedies available to the plaintiffs, given their infringement actions\nwere based on 35 U.S.C. § 271(e)(2), were those set forth in 35 U.S.C. § 271(e)(4),\nparaphrased as follows:\n(A) An order that the effective date of the FDA approval of the ANDA be no\nearlier than expiration of the patent (i.e., delaying the marketing and\nselling of the ANDA products); (B) An injunction to prevent commercialization of the ANDA products until the\npatents expire; (C) Only if the ANDA products were commercialized, damages or other\nmonetary relief; and (D) For infringement by a biological product, a permanent injunction in certain\ncircumstances.30 The flush language of 35 U.S.C. § 271(e)(4) provides (emphasis added): The remedies prescribed by subparagraphs (A), (B), (C), and (D)\nare the only remedies which may be granted by a court for an act of\ninfringement described in paragraph (2), except that a court may\naward attorney fees under section 285. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------28 The current statute includes subparagraph (d) relative to biologics, as discussed below. 29 35 U.S.C. § 285 provides that “The court in exceptional cases may award reasonable attorney fees to\nthe prevailing party. See Glaxo Group Limited v. Apotex, Inc., 376 F.3d 1339 (Fed. Cir. 2004)\n(addressing exceptional cases). See also Takeda Chem. Indus., Ltd. v. Mylan Labs., Inc., 459 F.Supp.2d\n227, 245-252 (S.D.N.Y. 2006) (“Sanctions Opinion”) and 2007 WL 840368 (S.D.N.Y. Mar. 21, 2007)\n(“Amount Opinion”), aff’d and rehearing en banc denied, 549 F.3d 1381 (Fed. Cir. 2009), cert. denied 130\nS. Ct. 106 (2009) (attorneys fees awarded for bad faith filing of the Paragraph IV certification and\nmisconduct during litigation). 30 See Addendum A, footnote 66 (status of amendments enacted as part of the 2010 health care reform). POSTU-139175-10 35 ----------------------------------------------------------------------------------------------------------------------------------none of the complaints alleged loss of profits.31\nCorporation X, in each law suit, in addition to denying its ANDA products would infringe\nthe patent claims that the plaintiffs alleged would be infringed:\n• denied that the patent claims that the plaintiffs alleged would be infringed were\nvalid; • asserted affirmative defenses that the patent claims that the plaintiffs alleged\nwould be infringed were invalid; and • counterclaimed that the patent claims the plaintiffs alleged would be infringed\nwere invalid. Corporation X’s prayers for relief requested that the patent claims at issue, which\nplaintiffs alleged were infringed by Corporation X filing the ANDAs, be declared invalid. -----------------------------------------------------------Thus, the pleadings were joined on the issues of infringement and validity. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------32 none of the claims included in the lawsuits filed against Corporation X,\nand none of Corporation X’s counterclaims, arose from a cause of action other than the\n31"
    },
    {
      "id": "legal-advice_43__8",
      "chunk_id": "8",
      "content": "-----------------------------------------------------------Thus, the pleadings were joined on the issues of infringement and validity. ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------32 none of the claims included in the lawsuits filed against Corporation X,\nand none of Corporation X’s counterclaims, arose from a cause of action other than the\n31 Corporation X had not commercialized the products the subject of the ANDAs in the United States; it\nhad merely filed ANDAs with paragraph IV certifications. 32 ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 36 filing of the ANDA pursuant to 35 U.S.C. § 271(e)(2).33 Corporation X’s ANDAs, like all\nANDAs, are assets that can be transferred on a stand-alone basis from one ANDA\nholder to another ANDA holder.34 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------Based on the facts and circumstances of this case it is clear that the infringement\nlitigation originated from Corporation X’s actions to obtain assets, FDA-approved\nANDAs, which can be sold or used in its trade or business until such time, if ever, the\nFDA withdraws its approval of the ANDAs.35 Approval can be withdrawn if the ANDA\nholder fails to comply with the requirements for keeping the ANDA effective or if, for\nexample, there are adverse reactions to the generic product that would cause the FDA\nto withdraw its approval. See Addendum A, last 3 pages (addressing requirements\nimposed by statute and regulation on an ANDA holder). Accordingly, the character of\nthe claims is capital since all claims are proximately related to, and have a direct nexus 33 If the claims in the litigation pleading were not all the same, each claim would need to be considered\nseparately, applying the origin of the claim test on a claim-by-claim basis. See Dye v. United States. 121\nF.3d 1399, 1406 (10th Cir. 1997) (“Where, as here, the litigation involves more than one claim, “the origin\n[of the claim] test must be applied separately to each part.\" ) The Dye Court noted that different appellate\ncourts have different positions on how attorney fees should be allocated among claims. 121 F.3d at\n1410. The Dye Court contrasted the Federal Circuit position with the 9th Circuit stating that in Baylin v.\nUnited States, 43 F.3d 1451, 1453 (Fed.Cir.1995), the Federal Circuit allocated “legal expenditures . . .\naccording to the approximate proportion of the lawyers' efforts attributable to the pursuit of each claim.” The Ninth circuit “by contrast, has rejected an approach similar to that of the Baylin court, ‘because it\nignores the contingent fee portion of the taxpayers' contract with their lawyers, and allocates fees only on\nthe basis of the hourly rate portion of the contract.’ Leonard v. Commissioner, 94 F.3d 523, 526 (9th\nCir.1996).” Thus, if allocations of the fees were necessary, the current position of the relevant circuit\ncourts would need to be considered in the allocation. 34 “An applicant may transfer ownership of its application. At the time of transfer the new and former\nowners are required to submit information to the Food and Drug Administration . . . . ” 21 C.F.R .\n§ 314.72(a).\n35"
    },
    {
      "id": "legal-advice_43__9",
      "chunk_id": "9",
      "content": "34 “An applicant may transfer ownership of its application. At the time of transfer the new and former\nowners are required to submit information to the Food and Drug Administration . . . . ” 21 C.F.R .\n§ 314.72(a).\n35 While Corporation X asserts that it did not hold title to an intangible and was not seeking title to an\nintangible (Facts, above, subsection titled “Corporation X’s Position”), as a matter of fact, there can be no\ndoubt that Corporation X was in the process of trying to obtain FDA approval of its ANDAs, with the\nANDAs the abbreviated applications with paragraph IV certifications that Corporation X prepared and filed\nwith the FDA. Corporation X was the holder (owner) of the ANDAs that it prepared and filed. See\nAddendum A (addressing the term “holder”). If Corporation X is arguing that it was not seeking title to the\nANDAs since it owned the applications it had prepared ab initio, the argument must fail as mere sophism. POSTU-139175-10 37 with, Corporation X’s actions to obtain new assets, i.e., FDA-approved ANDAs with\nparagraph IV certifications. Just the recital of the facts and circumstances, including the fact that an ANDA is a\ntransferrable commodity, provides an “adverse answer” to Corporation X’s position that\nit can deduct the fees. See Lincoln Savings, 403 U.S. 345 at 354 (holding the\nexpenditure at issue was not deductible as an ordinary and necessary business\nexpense because it created or enhanced “an additional asset and that, as an inevitable\nconsequence, the payment is capital in nature”). 36 B. Corporation X’s Reliance on the Primary Purpose Test Corporation X argues that it can deduct the fees based on the primary purpose test. Corporation X relies on Industrial Aggregate Company v. United States, 284 F.2d 639\n(8th Cir. 1960), which predates Gilmore, Woodward and Hilton Hotels. The primary\npurpose test used in Industrial Aggregate has been rejected by a long line of court\ncases, with some of said cases string cited at the beginning of Section I of the Law and\nAnalysis, above. Corporation X may have a primary purpose of increasing its long term\nincome, but that is a potential consequence to Corporation X’s fortunes, and does not\ncontrol. See United States v. Gilmore, 372 U.S. 39, 49 (1963)(“the origin and character\nof the claim with respect to which an expense was incurred, rather than its potential\nconsequences upon the fortunes of the taxpayer, is the controlling basic test . . .”). See\nalso Woodward v. Commissioner, 397 U.S. 572, 578 (1970) (“The [Gilmore] Court\nrejected a test that looked to the consequences of the litigation, and did not even\nconsider the taxpayer's motives or purposes in undertaking defense of the litigation, but\nrather examined the origin and character of the claim against the taxpayer, and found\nthat the claim arose out of the personal relationship of marriage.”). Corporation X also relies on Kornhauser v. United States, 276 U.S. 145 (1928), to\nsupport its position that it can deduct the expenditures because ANDA paragraph IV\nlitigation is common in the generic pharmaceutical industry."
    },
    {
      "id": "legal-advice_43__10",
      "chunk_id": "10",
      "content": "Corporation X also relies on Kornhauser v. United States, 276 U.S. 145 (1928), to\nsupport its position that it can deduct the expenditures because ANDA paragraph IV\nlitigation is common in the generic pharmaceutical industry. First, it is well established\nthat capital expenditures are not deductible merely because many members of an\nindustry have the same capital expenditures. See Commissioner v. Lincoln Savings &\nLoan Ass’n, 403 U.S. 345, 354 (1971) (“It is not enough, in order that an expenditure\nqualify as an income tax deduction, that it merely be . . . paid by all similarly [situated\ntaxpayers], or that it serves to fortify . . . purpose and operation.“). See also Lychuk v\nCommissioner, 116 T.C. 374, 393-416 (2001)(analyzing case law establishing that\nexpenditures are not ipso facto deductible because they are routine, recurring expenses 36 The payment at issue in Lincoln Savings was the additional premium paid to the Federal Savings and\nLoan Insurance corporation (FSLIC) for a secondary reserve maintained by the FSLIC, with Lincoln\nSavings pro rata share transferable and refundable under certain circumstances, one of the key facts for\ntreating the secondary reserve expenditure as paid to create or enhance an asset. POSTU-139175-10 38 of a business). 37 Second, the attorney fees at issue in Kornhauser were incurred in the\ndefense of a suit for an accounting of businesses earnings, a quintessential ordinary\nand necessary aspect of a business; not the creation or enhancement of a separate\nasset. Thus, Kornhauser does not apply to Corporation X’s facts, just as it did not apply\nin Safety Tube Corp. v Commissioner, 168 F.2d 787, 790 (6th Cir.1948) (distinguished\nKornhauser as a case not applicable when the litigation “struck at the very ownership of\nthe patent itself”). 38\nCorporation X also alleges that it incurred the fees at issue “to protect profits\nCorporation X . . . would receive from the sales of the future products.” Response to\nIDR #12 (emphasis added). Obliquely Corporation X is, in effect, admitting that the\nANDAs, once obtained, will be assets that will generate profits in the future. Thus, costs\nto create or enhance the ANDAs are within § 263, as addressed in Section II. Section II. § 263(a) and the 2004 Capitalization of Intangible Regulations There is no overall definition of “intangible” in the capitalization of intangibles\nregulations. As explained in the preamble to the 2004 capitalization of intangibles\nregulations: “The final regulations eliminate the use of, and the definition of, the term\n‘intangible asset’ that was contained in the proposed regulations. This change was\nmade in an effort to aid readability. The final regulations simply identify categories of\n‘intangibles’ for which amounts are required to be capitalized.” T.D. 9107, 2004-1 C.B.\n447, § II.A., General Principle of Capitalization. Treas. Reg. § 1.263(a)-4(b)(1) identifies the categories of intangibles that must be\ncapitalized as follows:\n(b) Capitalization with respect to intangibles--(1) In general. Except\nas otherwise provided in this section, a taxpayer must capitalize-(i) An amount paid to acquire an intangible (see\nparagraph (c) of this section)[39]; 37"
    },
    {
      "id": "legal-advice_43__11",
      "chunk_id": "11",
      "content": "Treas. Reg. § 1.263(a)-4(b)(1) identifies the categories of intangibles that must be\ncapitalized as follows:\n(b) Capitalization with respect to intangibles--(1) In general. Except\nas otherwise provided in this section, a taxpayer must capitalize-(i) An amount paid to acquire an intangible (see\nparagraph (c) of this section)[39]; 37 The change in litigation position announced in 2002 that cited Lychuk, Chief Counsel Notice CC-2002021, 2002 WL 32813480, addressed employee compensation, fixed overhead and de mimis transaction\ncosts, expenditures not addressed in this advice. The current position of the Commissioner on\ncapitalization is set for the capitalization of intangible regulations as in effect for the years at issue,\nregulations that were originally promulgated in 2004, T.D. 9107, 2004-1 C.B. 447.\n38 Urquhart v. Commissioner, 215 F.2d 17 (3rd Cir. 1954) and Corporation X’s arguments relative Treas. Reg. § 1.263(a)-4(d)(9) are addressed in footnote 60, below. 39 Amounts paid to acquire intangibles are not addressed herein since the regulations set forth that to be\nan acquired intangible the taxpayer must have acquired the intangible in a “purchase or similar\ntransaction.” Treas. Reg. § 1.263(a)-4(c)(1). While “purchase or similar transaction” is not defined in the\nregulations, reading the -4 regulations as a whole, the regulatory scheme would treat the ANDAs at issue\nas created, not acquired, because the ANDAs were, for example, not acquired from another POSTU-139175-10 39 (ii) An amount paid to create an intangible described in\nparagraph (d) of this section; (iii) An amount paid to create or enhance a separate\nand distinct intangible asset within the meaning of\nparagraph (b)(3) of this section; (iv) An amount paid to create or enhance a future\nbenefit identified in published guidance in the\nFederal Register or in the Internal Revenue Bulletin\n(see § 601.601(d)(2)(ii) of this chapter) as an\nintangible for which capitalization is required under\nthis section; [40] and (v) An amount paid to facilitate (within the meaning of\nparagraph (e)(1) of this section) an acquisition or\ncreation of an intangible described in paragraph\n(b)(1)(i), (ii), (iii) or (iv) of this section. Treas. Reg. § 1.263(a)-4(b)(1)(emphasis added). Thus, rather than providing an overall definition of intangibles, the regulations require\ncapitalization of expenditures that are within the categories identified in Treas. Reg.\n§ 1.263(a)-4(b)(1)(i.e., amounts paid to acquire or create an intangible, amounts paid to\ncreate or enhance a separate and distinct intangible and amounts paid to facilitate an\nacquisition or creation of an intangible, if within the subsections cross-referenced by\nTreas. Reg. § 1.263(a)-4(b)(1)) and not specifically exempted from capitalization (e.g.,\nthe 12-month rule). These identified categories of expenditures are construed broadly\nto comply with the regulatory regime of capitalization reflected in the regulations, taking\ninto account the facts and circumstances of each case. T.D. 9107, 2004-1 C.B. 447,\n§ II. D.\nConsidering the facts and circumstances of this case, and the intangible regulations as\na whole, the professional fees at issue are clearly within one or more of the identified\ncategories of expenditures that must be capitalized. At a minimum, the amounts were\npharmaceutical company for consideration. In Media Space Inc. v. Commissioner, 135 T.C. 424, 440-441\n(2010), after finding that the intangibles at issue were not, in substance, exchanged (as argued by the\ngovernment), the Court found that Treas."
    },
    {
      "id": "legal-advice_43__12",
      "chunk_id": "12",
      "content": "At a minimum, the amounts were\npharmaceutical company for consideration. In Media Space Inc. v. Commissioner, 135 T.C. 424, 440-441\n(2010), after finding that the intangibles at issue were not, in substance, exchanged (as argued by the\ngovernment), the Court found that Treas. Reg. § 1.263(a)-4(c)(1) did not apply because there was no\nexchange. There was no purchase based on the facts; however, the Court did not define “purchase or\nsimilar transaction.” 40 To date, no guidance has been published requiring the capitalization of expenditures with respect to\nintangibles not within the capitalization of intangible regulations that must be capitalized based solely on\nfuture benefit. POSTU-139175-10 40 paid to facilitate the creation of intangible assets and/or paid to create, facilitate or\nenhance separate and distinct intangibles,41 as addressed in the below subsections. A. Amounts Paid to Create an Intangible or\nFacilitate the Creation of an Intangible Treas. Reg. § 1.263(a)-4(d) (hereinafter the “-4(d) regulations”) addresses the treatment\nof created intangibles, with other sections of the intangible regulations addressing the\ntreatment of amounts paid to facilitate the creation of an intangible. As explained below,\namounts paid to obtain ANDAs are paid to create intangibles within the meaning of the\n-4(d) regulations on created intangibles, with the professional fees at issue paid to\nfacilitate the creation of said ANDAs. The -4(d) regulations (created intangibles), in subsection (5)(i), require the capitalization\nof amounts paid to obtain rights from a government, treating such payments as paid to\ncreate an intangible. Specifically, the -4(d) regulations provide, inter alia:\n(i) In general. – A taxpayer must capitalize amounts paid to a\ngovernment agency to obtain, renew, renegotiate, or upgrade its\nrights under a trademark, trade name, copyright, license, permit,\nfranchise, or other similar right granted by that governmental\nagency. Treas. Reg. § 1.263(a)-4(d)(5)(i)(emphasis added). Payments to the FDA (a government agency) to obtain the right to market and sell a\nnew drug in the United States (obtained via FDA approval of a NDA or an ANDA, as\naddressed in Addendum A) would be within Treas. Reg. § 1.263(a)-4(d)(5)(i). 41 To the extent Corporation X contends that Treas. Reg. §1.263(a)-4(d)(9) is not applicable because the\nFDA-approved ANDAs being created by Corporation X did not yet exist so Corporation X could not be\ndefending or perfecting title to FDA-approved ANDAs, that is a moot issue since the fees at issue are\nclearly capitalizable as paid to facilitate, directly or indirectly, the creation of the ANDAs. To the extent\nCorporation X contends Urquhart v. Commissioner, 215 F.2d 17 (3rd Cir. 1954), establishes that fees to\ndefend patent infringement suits are per se outside the scope of Treas. Reg. §1.263(a)-4(d)(9),\nCorporation X errs. In Urquhart, at the appellate level, it was “conceded that no question of title was\ninvolved.” 215 F.2d at 19 (emphasis added). Thus, Urquhart is the quintessential example of a case that\ndid not involve title since it was conceded that the case did not involve title. Moreover, the joint venture\nthat deducted the fees in Urquhart was merely protecting its earnings from licensing two patents that it did\nnot own."
    },
    {
      "id": "legal-advice_43__13",
      "chunk_id": "13",
      "content": "Thus, Urquhart is the quintessential example of a case that\ndid not involve title since it was conceded that the case did not involve title. Moreover, the joint venture\nthat deducted the fees in Urquhart was merely protecting its earnings from licensing two patents that it did\nnot own. See Urquhart v. Commissioner, 20 T.C. 944, 945 (1953), rev’d, 215 F.2d 17 (3rd Cir. 1954)\n(“Although title to these two patents was retained by Radcliffe M. Urquhart and George Gordon Urquhart,\nthey invested the joint venture with power to make arrangements for the administration and licensing of\nthese patents and to receive the royalties earned therefrom.”). The joint venture’s sole business income\nwas from collecting the royalties generated by patents it did not own. See Urquhart v. Commissioner, 20\nT.C. 944, 945 (1953), rev’d, 215 F.2d 17 (3rd Cir. 1954)(“From 1942 through 1946 [the years at issue] the\nsole business conducted by the joint venture was the licensing of the two patents.”). Accordingly,\nUrquhart does not establish precedent for cases where the litigation is, in whole or part, to protect or\nperfect title to patents. POSTU-139175-10 41 Specifically, an ANDA fits one of more of the non-exclusive list of types of governmentgranted rights that are treated as created intangibles, e.g., “license, permit, franchise or\nother similar right granted by that governmental agency.” For example, an ANDA is\nwithin the definition of a franchise as used in the 2004 capitalization of intangible\nregulations. 42 While none of the amounts at issue were paid to the government, the regulations\nspecifically require costs that facilitate the creation of an intangible, such as\ngovernmental rights, to be capitalized. Treas. Reg. § 1.263(a)-4(b)(1) (iv). The\nregulations provide clear guidance on what type of costs are treated as facilitating the\ncreation of intangibles as follows:\n(e) Transaction costs--(1) Scope of facilitate--(i) In general. Except\nas otherwise provided in this section, an amount is paid to facilitate\nthe acquisition or creation of an intangible (the transaction) if the\namount is paid in the process of investigating or otherwise pursuing\nthe transaction. Whether an amount is paid in the process of\n42 While the -4(d) regulations addressing created intangibles do not define the term “franchise,” the term\nis defined within the capitalization of intangible regulations addressing acquired intangibles. “Franchise”\nfor purpose of acquired intangibles has the same meaning the term is given in Treas. Reg. § 1.1972(b)(10). Treas. Reg. § 1.263(a)-4(c)(1)(viii). Treas. Reg. § 1.197-2(b)(10) states that a “franchise has the\nmeaning given in I.R.C. § 1253(b)(1) and “includes any agreement that provides one of the parties to the\nagreement with the right to distribute, sell, or provide goods, services, or facilities, within a specified area.” Treas. Reg. § 1.197-2(b)(10). Section 1253(b)(1) defines a franchise to “include an agreement which\ngives one of the parties to the agreement the right to distribute, sell, or provide goods, services, or\nfacilities, within a specified area.\" Corporation X’s ANDAs fit neatly into the I.R.C. § 1253(b)(1) definition since the ANDAs give Corporation\nX the right to market and sell its ANDA products within the United States, a territory that encompasses the\nentire country."
    },
    {
      "id": "legal-advice_43__14",
      "chunk_id": "14",
      "content": "Corporation X’s ANDAs fit neatly into the I.R.C. § 1253(b)(1) definition since the ANDAs give Corporation\nX the right to market and sell its ANDA products within the United States, a territory that encompasses the\nentire country. Courts have noted that Congress provided an \"expansive definition\" of franchise to\n“include” agreements to sell or distribute goods within a specified area, which does not exclude other\nthings otherwise within the meaning of a franchise. See, e.g., Jefferson-Pilot Corp. v. Commissioner, 98\nT.C. 435, 443 (1992), aff'd 995 F.2d 530 (4th Cir. 1993) (FCC licenses are agreements “between the\nFederal Government and the licensee, under which the licensee agrees to provide the service of radio\nbroadcasting within a specified area in exchange for the right to broadcast”). See also, Jefferson-Pilot\nCorp. v. Commissioner, 995 F. 2d 530 at 531 (4th Cir. 1993)(“The definition of term ‘franchise’ is\nsufficiently broad to include licenses issued by the FCC.”). That the right to market and sell came from the FDA, not the Federal Communications Commission\n(FCC), is a distinction without a difference – both the FDA and FCC are granting, for a territory,\ncommercialization rights. See also Addendum A, last 3 pages (enumerating the quality controls and other\nrestrictions imposed on the ANDA holder to retain the rights to market and sell, with the controls similar in\nnature to the “strings” a franchiser would retain over its franchise, e.g., quality controls). In addition, the\nidentified categories of expenditures that must be capitalized are construed broadly, and not limited by\nnarrow technical arguments. T.D. 9107, 2004-1 C.B. 447 § II. D. Accordingly, FDA-approved ANDAs\nthat allow the marketing and selling of new drugs in the United States are franchises within the meaning\nof Treas. Reg. § 1.263(a)-4(d)(5)(i). POSTU-139175-10 42 investigating or otherwise pursuing the transaction is determined\nbased on all of the facts and circumstances. In determining\nwhether an amount is paid to facilitate a transaction, the fact that\nthe amount would (or would not) have been paid but for the\ntransaction is relevant, but is not determinative. Treas. Reg. § 1.263(a)-4(e)(1)(emphasis added). The term “transaction,” as used above, is also clearly defined in the regulations, as\nfollows:\n(3) Transaction. For purposes of this section, the term transaction\nmeans all of the factual elements comprising an acquisition or\ncreation of an intangible and includes a series of steps carried out\nas part of a single plan. Thus, a transaction can involve more than\none invoice and more than one intangible. For example, a\npurchase of intangibles under one purchase agreement constitutes\na single transaction, notwithstanding the fact that the acquisition\ninvolves POSTU-139175-10 43 multiple intangibles and the amounts paid to facilitate the\nacquisition are capable of being allocated. . . .\nTreas. Reg. § 1.263(a)-4(e)(3)(emphasis added). The transactions at issue in this case, which generated the fees at issue, arose from\nCorporation X’s filing of ANDAs with paragraph IV certifications to obtain FDA-approved\nANDAs allowing Corporation X to market and sell generic pharmaceuticals in the\nterritory of the United States prior to the expiration of the United States patents for the\nreferenced NDA-approved drugs."
    },
    {
      "id": "legal-advice_43__15",
      "chunk_id": "15",
      "content": "Corporation X was pursuing obtaining each ANDA as\npart of one overall transaction for FDA approval of each ANDA to be able to market and\nsell the new drugs the subject of each ANDA in the United States (e.g., license, permit,\nfranchise or similar right to market and sell its generic drugs in the United States). On\nan ANDA-by-ANDA basis Corporation X was seeking to obtain FDA-approved ANDAs\nby carrying out the series of steps required by the statutory and regulatory regime to\nobtain approval of its ANDAs. The steps included notifying the NDA holders and\npatentees of the filing of an ANDA with a paragraph IV certification, with that\ncertification necessitating outside counsels to research the patents. Once the NDA\nholders and patentees filed suit, Corporation X had to defend itself to obtain FDA\napproval of an ANDA effective before the expiration of the patents. Accordingly, the\nprofessional fees incurred in researching the paragraph IV certifications and\ninfringement litigation defense fees were incurred to facilitate obtaining governmentalgranted rights and thus must be capitalized. Alternatively, even if one could argue the fees did not directly facilitate obtaining the\nFDA-approved ANDAs, the fees would be an indirect payment relative to obtaining the\nANDAs that also must be capitalized, as were the attorney fees in the following\nexamples set forth in Treas. Reg. §1.263(a)-4(l):\n(l) Examples. The rules of this section are illustrated by the following\nexamples in which it is assumed that the Internal Revenue Service\nhas not published guidance that requires capitalization under\nparagraph (b)(1)(iv) of this section (relating to amounts paid to\ncreate or enhance a future benefit that is identified in published\nguidance as an intangible for which capitalization is required):\nExample 1. License granted by a governmental unit. (i) X\ncorporation pays $25,000 to state R to obtain a license to sell\nalcoholic beverages in its restaurant. The license is valid\nindefinitely, provided X complies with all applicable laws regarding\nthe sale of alcoholic beverages in state R. X pays its outside\ncounsel $4,000 for legal services rendered in preparing the license\napplication and otherwise representing X during the licensing\nprocess. In addition, X determines that $2,000 of salaries paid to its\nemployees is allocable to services rendered by the employees in\nobtaining the license. POSTU-139175-10 44 (ii) X's payment of $25,000 is an amount paid to a governmental\nunit to obtain a license granted by that agency, as described in\nparagraph (d)(5)(i) of this section. The right has an indefinite\nduration and constitutes an amortizable section 197 intangible. Accordingly, as provided in paragraph (f)(3) of this section, the\nprovisions of paragraph (f) of this section (relating to the 12-month\nrule) do not apply to X's payment. X must capitalize its $25,000\npayment to obtain the license from state R.\n***\n(iv) X's payment of $4,000 to its outside counsel is an amount paid\nto facilitate the creation of an intangible, as described in paragraph\n(e)(1)(i) of this section. Because X's transaction costs do not\nexceed $5,000, X's transaction costs are de minimis within the\nmeaning of paragraph (e)(4)(iii)(A) of this section. Accordingly, X is\nnot required to capitalize the $4,000 payment to its outside counsel\nunder this section. Treas. Reg. § 1.263(a)-4(l)(1)(emphasis added)."
    },
    {
      "id": "legal-advice_43__16",
      "chunk_id": "16",
      "content": "Because X's transaction costs do not\nexceed $5,000, X's transaction costs are de minimis within the\nmeaning of paragraph (e)(4)(iii)(A) of this section. Accordingly, X is\nnot required to capitalize the $4,000 payment to its outside counsel\nunder this section. Treas. Reg. § 1.263(a)-4(l)(1)(emphasis added). In the example quoted above, the $4,000 paid to outside counsel was below the de\nminimus safe harbor so was not capitalizable. In this case, the attorney fees for each\nANDA far exceed $5,000, and must be aggregated by ANDA because the investigations\nand litigation fees for each ANDA were part of a series of steps in a plan to obtain an\nFDA-approved ANDA. Treas. Reg. § 1.263(a)-4(e)(3). Just as the license addressed in\nthe example, Corporation X’s ANDAs are effective indefinitely provided Corporation X\ncomplies with all applicable laws and regulations, and the drugs do not have adverse\nside effects that cause the FDA to withdraw its approval. Accordingly, the attorney fees\nCorporation X incurred that are the subject of this advice must be capitalized because\nthey were incurred to facilitate, directly or indirectly, obtaining the FDA-approved\nANDAs that granted Corporation X the right to market and sell its ANDA products in the\nUnited States. See also Treas. Reg. § 1.263(a)-4(e)(5), Example 3. B. Amounts Paid to Create or Enhance a Separate and Distinct Intangible The capitalization of intangible regulations provide that amounts paid to create or\nenhance a separate and distinct intangible must be capitalized. Treas. Reg.\n§ 1.263(a)-4(b)(1)(iii). Treas. Reg. § 1.263(a)-4(b)(3)(i) defines separate and\ndistinct asset, as follows: The term separate and distinct intangible asset means a property\ninterest of ascertainable and measurable value in money's worth\nthat is subject to protection under applicable State, Federal or POSTU-139175-10 45 foreign law and the possession and control of which is intrinsically\ncapable of being sold, transferred or pledged (ignoring any\nrestrictions imposed on assignability) separate and apart from a\ntrade or business. . . . The determination of whether a payment\ncreates a separate and distinct intangible asset is made based on\nall of the facts and circumstances existing during the taxable year\nin which the payment is made. Treas. Reg. § 1.263(a)-4(b)(3)(i)(emphasis added). ANDAs are within the definition of separate and distinct intangible assets. ANDAs can\nbe transferred from the sponsor (original applicant) to another, separate and apart from\na trade or business. 21 C.F.R . § 314.72(a). ANDAs are subject to protection under\nFederal law. For example, when an ANDA holder has 180 days of exclusivity, federal\nlaw precludes any other generic for the referenced NDA from being approved during the\nperiod of exclusivity. 21 U.S.C. § 355(j)(5)(B)(iii)(IV)(2010). An entire profitable\nindustry, the generic pharmaceutical industry, has evolved around the value of the\nANDAs.43 While it would take an expert, the expected stream of income from each\nANDA could be projected and then valued at its net present value. Accordingly, each\nANDA is a separate and distinct asset with the professional fees paid to enhance or\nfacilitate the creation of these separate and distinct assets capitalized. Treas. Reg.\n§§ 1.263(a)-4(b)(1)(v) and -4(b)(3)(i). Treas."
    },
    {
      "id": "legal-advice_43__17",
      "chunk_id": "17",
      "content": "Accordingly, each\nANDA is a separate and distinct asset with the professional fees paid to enhance or\nfacilitate the creation of these separate and distinct assets capitalized. Treas. Reg.\n§§ 1.263(a)-4(b)(1)(v) and -4(b)(3)(i). Treas. Reg. § 1.263(a)-4(e)(3) provides that a “transaction” for purposes of the -4\nregulations “includes a series of steps carried out as part of a single plan.” Specifically\nstating that\n(3) Transaction. For purposes of this section, the term transaction\nmeans all of the factual elements comprising an acquisition or\ncreation of an intangible and includes a series of steps carried out\nas part of a single plan. Thus, a transaction can involve more than\none invoice and more than one intangible. For example, a\npurchase of intangibles under one purchase agreement constitutes\na single transaction, notwithstanding the fact that the acquisition\ninvolves multiple intangibles and the amounts paid to facilitate the\nacquisition are capable of being allocated. Treas. Reg. § 1.263(a)-4(e)(3) (emphasis added). ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------43 See generally Generic Pharmaceutical Association Providing Extraordinary Savings for Americans. http://www.gphaonline.org/ (last visited on June 14, 2011) POSTU-139175-10 46 --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------44 ----------------------------------------------------------------------------------------------------------------------- 45 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------44 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------45 -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- POSTU-139175-10 47 ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------CASE DEVELOPMENT, HAZARDS AND OTHER CONSIDERATIONS Please provide a copy of the 30-day letter, when issued, and provide a copy of\nCorporation X’s Protest, if any, when received. This writing may contain privileged information. Any unauthorized disclosure of this\nwriting may undermine our ability to protect the privileged information. If disclosure is\ndetermined to be necessary, please contact this office for our views. By: _____________________________ Marjory A. Gilbert\nIndustry Counsel (Pharmaceuticals and Biotech)\nRetailers, Food, Pharmaceuticals & Healthcare\nLarge Business & International\nOffice of Chief Counsel, IRS Attachments: Addendum -A POSTU-139175-10 48 ------------------------------------------------------------------------------------------------------------------------------In order to market or sell a new drug in the United States, the new drug must be\napproved by the Food and Drug Administration (FDA). Federal Food, Drug, and\nCosmetic Act, 21 U.S.C. § 355(a)(2010) (“No person shall introduce or deliver for\nintroduction into interstate commerce any new drug, unless an approval of an\napplication filed pursuant to subsection (b) or (j) of this section is effective with respect\nto such drug.”). 46 The term “new drug” in § 355(a) includes generic drugs. United\nStates v. Generix Drug Corporation, 460 U.S. 453, 461 (1983) (“In summary, a generic\ndrug product is a ‘drug’ within the meaning of § 201(g)(1) of the Act.”). A. New Drug Application (NDA) The 2007 Coordinated Issue Paper on taxation of drug development agreements47\nsummarizes the process for developing a new (non-generic) drug for FDA approval as\nfollows: The pharmaceutical/biotech drug development process is generally\ncomposed of four stages: Preclinical or discovery research, clinical 46 The Westlaw electronic research service has a red flag on 21 U.S.C. § 355 asserting that § 355 was\nheld unconstitutional and not severable by Florida v. United States Department of Health and Human\nServices, 2011 WL 285683 (N.D. Fla. Jan. 31, 2011), clarified and order provisionally stayed in Florida v.\nUnited States Department of Health and Human Services, 2011 WL 723117 (N.D. Fla. March 3, 2011),\naff’d in part and rev’d in part, 2011 WL 3519178 (11th Cir.)(hereinafter collectively Florida vs. HHS)."
    },
    {
      "id": "legal-advice_43__18",
      "chunk_id": "18",
      "content": "Florida v HHS does not address § 355, per se, and does not address § 355 as in force for the years at\nissue. Rather, Florida v HHS addressed the 2010 health reform legislation. Specifically Florida v HHS\nholds unconstitutional the requirement that individuals purchase health insurance in the Patient Protection\nand Affordable Care Act (ACA), Pub. L. No. 111-148, 124 Stat. 119 (2010), as amended by section 1404\nof the Health Care and Education Reconciliation Act of 2010 (HCERA), Pub. L. No. 111-152, 124 Stat.\n1029 (2010) (hereinafter collectively referred to as the ACA), with the District Court in Florida v HHS also\nholding the insurance requirement cannot be severed so the entire ACA is unconstitutional. However, the\nEleventh Circuit reversed the District Court’s severability holding and other cases have upheld the\nconstitutionality of the minimum essential coverage requirements, including Mead v. Holder, 766 F. Supp\n2d. 16, 2011 WL 611139 (D.D.C. 2011); Liberty University, Inc. v. Geithner, 753 F.Supp.2d 611, 2010 WL\n4860299 (W.D.Va. 2010); and Thomas More Law Center v. Obama, 720 F.Supp.2d 882 (E.D.Mich.2010),\naff’d, 2011 WL 2556039, (6th Cir. Mich.) Jun 29, 2011, Petition for Writ of Certiorari, 2011 WL 3860758\n(No. 11-117) (July 26, 2011). See Congressional Research Service, Requiring Individuals to Obtain\nHealth Insurance: A Constitutional Analysis, August 26, 2011, at 25-32 (analysis of legal challenges to the\nminimum essential coverage requirement). The provisions of the ACA that impact 21 U.S.C. § 355 are\n§§ 7002 and 10609, which amended 21 U.S.C. § 355 to add language relative to biologics and labeling,\nrespectively. See Pub. L. No. 111-148, 124 stat. 119 at 816-817, 820, 860, and 1014-15 (2010). Neither\namendment impacts the constitutionality of 21 U.S.C. § 355 as in force and effect in the years here at\nissue. 47 Non Refundable Upfront Fees, Technology Access Fees, Milestone Payments, Royalties and Deferred\nIncome under a Collaboration Agreement, Tax Notes Today, October 18, 2007, 2007 TNT 204-17. POSTU-139175-10 49 development, regulatory approval, and post marketing. These\nstages take approximately 10 to 12 years to complete. In the preclinical or discovery research stage (typically the first two\nyears of the discovery/development process), a compound is tested\non animals and non-human systems. If the compound/molecule\nlooks promising at this stage, it is patented. The patent prevents\nother companies from freely using the same compound/molecule\nfor 20 years (life span of a patent). The Food and Drug\nAdministration (FDA) established a set of standards (called \"Good\nLaboratory Practice\") for this stage of development to ensure\nquality of animal testing and the resultant data for an Investigational\nNew Drug Application (IND). If the IND is approved by the FDA,\ntesting of the compound/molecule in humans can begin. Th[e] second stage is known as clinical development. Clinical\ndevelopment (typically spans 5 to 7 years or years 3 through 10 of\nthe discovery/development process) is normally conducted in three\nphases. In Phase I, the first trials in humans are conducted for\nsafety, tolerance and pharmacokinetics. In Phase II, testing is done\nto evaluate effectiveness, dosage and safety in selected\npopulations of patients with the disease or condition to be treated,\ndiagnosed or prevented."
    },
    {
      "id": "legal-advice_43__19",
      "chunk_id": "19",
      "content": "In Phase I, the first trials in humans are conducted for\nsafety, tolerance and pharmacokinetics. In Phase II, testing is done\nto evaluate effectiveness, dosage and safety in selected\npopulations of patients with the disease or condition to be treated,\ndiagnosed or prevented. In Phase III, expanded clinical trials are\nconducted to gather additional evidence to verify dosage and\neffectiveness for specific indications and to better understand\nsafety and adverse effects. These are large-scale trials typically\ninvolving thousands of patients to prove effectiveness against a\nspecific disease or condition. The third stage, known as the regulatory approval stage, begins\nafter Phase III trials have been completed (typically spans 12 to 18\nmonths or years 11 and 12 of the discovery/development process). Sponsors file a New Drug Application (NDA) with the FDA to obtain\nauthorization to market a new pharmaceutical product. The NDA\nconsists of clinical and non clinical data on the product's safety and\neffectiveness and a full description of the methods, facilities, and\nquality controls employed in manufacturing and packaging. Until\nthe FDA grants authorization, a drug sponsor cannot market the\ndrug in the United States. The final stage, post-marketing studies (also called Phase IV),\noccurs after the product has received FDA approval. These studies\nare performed to determine the incidence of adverse reactions, to\ndetermine the long-term effect of a drug, to study a patient POSTU-139175-10 50 population not previously studied, and to conduct marketing\ncomparisons against other products and other uses. See Josephine C. Babiarz and Douglas J. Pisano, Overview of FDA and Drug\nDevelopment, FDA Regulatory Affairs, A Guide for Prescription Drugs, Medical Devices\nand Biologics, 1-32. (Douglas J. Pisano and David S. Mantus, eds., 2nd Ed., 2008)\n(Summarizing the statutory and regulatory regime for New Drug Applications, with\ncitations). New Drug Applications (NDAs) can be transferred from the original sponsor (entity that\nsubmitted the application for the NDA) to another, provided the requirements imposed\nby the FDA are met.48 The entity that holds the rights to the NDA is sometimes referred\nto as the holder of the NDA. See aaiPharma, Inc., v. Thompson, 296 F.3d 227 (4th Cir.\n2002) (referring to the current owner of an FDA-approved NDA as the NDA holder when\naddressing the FDA’s role in ensuring the accuracy of patent information in the FDApublished document “Approved Drug Products With Therapeutic Equivalence\nEvaluations,” also known as the Orange Book). The NDA must disclose all patents that cover the drug, with the NDA holder required to\nnotify the FDA of all new patents that subsequently cover the drug after the filing of the\nNDA. 21 C.F.R. § 314.53 (2009). The FDA posts the patent information provided by\nthe NDA holder to its publication called “Approved Drug Products With Therapeutic\nEquivalence Evaluations,” also known as the “Orange Book,” available in hard copy or\nelectronically on the FDA website. 49\nDrugs that can be marketed and sold in the United States pursuant to an approved NDA\nare likely to have a trademarked name, and are generally referred to as “branded drugs”\nwhether or not the patents covering the drugs have expired. 50 The term “pioneer drug”\nwas used in early case law to refer to a drug with an FDA-approved NDA."
    },
    {
      "id": "legal-advice_43__20",
      "chunk_id": "20",
      "content": "50 The term “pioneer drug”\nwas used in early case law to refer to a drug with an FDA-approved NDA. See United\nStates v. Generix Drug Corporation, 460 U.S. 453, 454-55 (1983)(“The term ‘generic\ndrug’ is used to describe a product that contains the same active ingredients but not\nnecessarily the same excipients as a so-called “pioneer drug” that is marketed under a\nbrand name.”); Actavis Elizabeth LLC v FDA, 625 F. 3d 760, 761-62, 764 (D.C. Cir.\n2010) (“So-called ‘new drug applications’ - required for ‘pioneer’ drugs that have never\nbefore received FDA approval - must be supported by full reports of investigations\nshowing the drug is safe and effective.”). Current literature uses the term “innovator\n48 21 C.F.R. § 314.72(a)(2009) (“An applicant may transfer ownership of its application. At the time of\ntransfer the new and former owners are required to submit information to the Food and Drug\nAdministration . . . . ”).\n49 Orange Book Publications, U.S. Food and Drug Administration,\nhttp://www.accessdata.fda.gov/scripts/cder/ob/eclink.cfm (last visited on May 20, 2011). 50 Pharmaceutical companies generally do not submit NDAs on drugs that are not, at least initially,\ncovered by patents due to the time and expense of developing a new drug. POSTU-139175-10 51 drug” without specifying if the term “innovator drug” means the same as “pioneer drug”\nor refers only to innovator drugs that have extended exclusivity. 51 B. Abbreviated new drug application (ANDA) Initially, most generic drugs had to be approved pursuant to the same process\napplicable to pioneer drugs. See aaiPharma Incorporated v. Thompson, 296 F.3d 227,\n230-231 (4th Cir. 2002) (“Prior to Hatch-Waxman’s passage in 1984, both pioneer\n(brand name) and generic drug manufacturers who wished to bring a drug to market\nwere required to file a New Drug Application (NDA) with the FDA.”) In 1984, an abbreviated process for approving generic drugs was established by the\nDrug Price Competition and Patent Term Restoration Act of 1984 (commonly known as\nthe Hatch-Waxman Act), Pub. L. No. 98–417, 98 Stat. 1585 (1984) (codified as\namended at 21 U.S.C. § 355 (2010) and 35 U.S.C. § 271(e)(2010)).52 In general, under\nthe Hatch-Waxman Act, an ANDA “piggy-backs” off an approved NDA. In lieu of\nreplicating the time intensive and expensive studies preformed to obtain an NDA, an\napplicant for an ANDA can establish that its generic drug is the bioequivalent53 of the\n51 Pursuant to 21 U.S.C. §355(c)(3)(E)(i)-(v)(2010) (See also § 355(j)(5)(F)(i)-(v)), certain innovative drugs\nwith an FDA-approved NDA can be granted additional years of exclusivity (3 years for a new use or\ndosage based on additional clinical trails and 5 years for a new chemical entity). See Abbott Laboratories\nv. Young, 920 F.2d 984, 986 (D.C. Cir. 1990) (“Congress thereby sought to encourage innovation in the\ndrug industry, by rewarding a pioneer drug with . . . exclusivity, while protecting consumers from unduly\nhigh prices by refusing to give a long period of market exclusivity to drugs which required no new\nresearch effort.”); Actavis Elizabeth LLC v. FDA, 625 F. 3d 760 (D.C. Cir. 2010)(addressing a generic\ndrug makers challenge to the award of five years exclusivity to a branded drug)."
    },
    {
      "id": "legal-advice_43__21",
      "chunk_id": "21",
      "content": "Separate statutory\nprovisions provide for patent extensions in certain circumstances (e.g., an extension of the patent life\nbased on the time the FDA spent reviewing the drug or the time the United States Patent Office spent\nreviewing the patent.) 35 U.S.C. §§ 155 and 156 See Mary W. Bourke and M. Edward Danberg, Current\nTrends in Hatch-Waxman Patent Litigation: A System Still in Flux, Practicing Law Institute, 878 PLI/Pat\n939, §§ I.C.6, 7 and 8 (2006) (patent extensions and exclusivity). 52 The 1984 changes did not include an abbreviated process for approving biologic drugs. See Asim\nVarma, Son B. Nguyen and Justin P. Hedge, The FTC Reports on Follow-On Biologics and Authorized\nGenerics: Applying Lessons from Hatch-Waxman to Promote Competition, Antitrust 41, 42 (Fall,\n2009)(“Hatch-Waxman does not apply to biologic products”). A pathway for generic biologics was\nprovided for in the \"Biologics Price Competition and Innovation Act of 2009, which was enacted as part of\nthe Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119 (2010), as amended\nby section 1404 of the Health Care and Education Reconciliation Act of 2010, Pub. L. No. 111-152, 124\nStat. 1029 (2010), with the pathway legislation in § 7002 of Pub. L. No. 111-148, 124 stat. 119 at 816817, 820 and 860. See 4 Health L. Prac. Guide Appendix A (May, 2011) (“The healthcare reform\nlegislation, as amended by the reconciliation act (Publ. L. No. 111-152), creates a clear regulatory\npathway for approving follow-on biologics.”). See footnote 66, above (constitutionality of the Patient\nProtection and Affordable Care Act). 53 “’Bioequivalence’ means that the active ingredient is absorbed at the same rate and to the same extent\nfor the generic drug as for the innovator drug.” Mary W. Bourke and M. Edward Danberg, Current Trends\nin Hatch-Waxman Patent Litigation: A System Still in Flux, Practicing Law Institute, 878 PLI/Pat 939,\n§ I.C.2. (2006). POSTU-139175-10 52 drug in an approved NDA. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).54\nSee 21 C.F.R. §§ 314.1- 314.650 (2011) (Applications for FDA Approval to Market a\nNew Drug). See also Mylan Pharmaceuticals, Inc. v. FDA, 454 F. 3d 270, 272 (4th Cir.\n2007)(“The Hatch-Waxman Act made it easier to obtain FDA approval of generic\ndrugs.”). The Hatch-Waxman Act sought to correct two distortions in the law, as explained in Eli\nLilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990). First, the holder of a patent relating to such products [drugs subject\nto FDA approval] would as a practical matter not be able to reap\nany financial rewards during the early years of the [patent] term. When an inventor makes a potentially useful discovery, he\nordinarily protects it by applying for a patent at once. Thus, if the\ndiscovery relates to a product that cannot be marketed without\nsubstantial testing and regulatory approval, the “clock” on his patent\nterm will be running even though he is not yet able to derive any\nprofit from the invention. The second distortion occurred at the other end of the patent term."
    },
    {
      "id": "legal-advice_43__22",
      "chunk_id": "22",
      "content": "Thus, if the\ndiscovery relates to a product that cannot be marketed without\nsubstantial testing and regulatory approval, the “clock” on his patent\nterm will be running even though he is not yet able to derive any\nprofit from the invention. The second distortion occurred at the other end of the patent term. In 1984, the Court of Appeals for the Federal Circuit decided that\nthe manufacture, use, or sale of a patented invention during the\nterm of the patent constituted an act of infringement, see 35 U.S.C.\n§ 271(a), even if it was for the sole purpose of conducting tests and\ndeveloping information necessary to apply for regulatory approval. Since that activity could not be commenced by those who planned\nto compete with the patentee until expiration of the entire patent\nterm, the patentee's de facto monopoly would continue for an often\nsubstantial period until regulatory approval was obtained. In other\nwords, the combined effect of the patent law and the premarket\nregulatory approval requirement was to create an effective\nextension of the patent term. The 1984 Act sought to eliminate this distortion from both ends of\nthe patent period. Section 201 of the Act established a patent-term\nextension for patents relating to certain products that were subject 54 More specifically, “[t]o obtain FDA approval, a generic manufacturer must ordinarily show, among other\nthings, that its product has the same active ingredients as an approved brand-name drug; that ‘the route\nof administration, the dosage form, and the strength of the new drug are the same’ as the brand-name\ndrug; and that its product is ‘bioequivalent’ to the brand-name drug. [21 U.S.C.] §§ 355(j)(2)(A)(ii)(iii)(iv). By eliminating the need for generic manufacturers to prove their drugs’ safety and efficacy independently,\nthe Hatch-Waxman Amendments allow generic manufacturers to bring drugs to market much less\nexpensively.” Pliva v. Mensing, 131 S. Ct. 2567, 2583 (June 23, 2011)(quoting from dissent by Justice\nSotomayor). POSTU-139175-10 53 to lengthy regulatory delays and could not be marketed prior to\nregulatory approval. *** The distortion at the other end of the patent period was addressed\nby § 202 of the Act. That added to the provision prohibiting patent\ninfringement, . . . [a section] establishing that “it shall not be an act\nof infringement to make, use, or sell a patented invention ... solely\nfor uses reasonably related to the development and submission of\ninformation under a Federal law which regulates the manufacture,\nuse, or sale of drugs.” This allows competitors, prior to the\nexpiration of a patent, to engage in otherwise infringing activities\nnecessary to obtain regulatory approval. 469 U.S. at 669-71 (citations and footnotes omitted). Thus, while prior to the Hatch-Waxman Act non-authorized generic equivalents of\npatented drugs could not be developed without infringing the patents that covered the\ndrug,55 under the 1984 revisions the unauthorized use of a patented drug for the\npurposes of developing a generic drug no longer constitutes an act of infringement. 56\n35 U.S.C. § 271(e)(2010). However, the “safe harbor” from infringement terminates when the ANDA is submitted\nto the FDA. The termination of the “safe harbor” occurs, as applicable, because the\nHatch-Waxman"
    },
    {
      "id": "legal-advice_43__23",
      "chunk_id": "23",
      "content": "56\n35 U.S.C. § 271(e)(2010). However, the “safe harbor” from infringement terminates when the ANDA is submitted\nto the FDA. The termination of the “safe harbor” occurs, as applicable, because the\nHatch-Waxman Act makes filing of an ANDA prior to the expiration of the patents\ncovering the approved NDA an act of infringement (35 U.S.C.\n§ 271(e)(2)(2010)), which has limited remedies (35 U.S.C. § 271(e)(4)).57 As explained\nin Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990), after quoting from 35 U.S.C.\n§ 271(e)(2) and (e)(4):58\n55 Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858 (Fed.Cir.1984), cert. denied, 469 U.S. 856\n(1984). 56 See Proveris Scientific Corp. v. Innovasystems, Inc, 536 F. 3d 1256 (Fed. Cir. 2008)(exemption from\ninfringement does not apply if the invention is not subject to FDA approval). 57 In exceptional cases, pursuant to 35 U.S.C. § 271(e)(4) attorney fees can be awarded to the NDA\nholder if it prevails in an infringement actions against the sponsor of an ANDA. Yamanouchi\nPharmaceutical Co., Ltd. v. Danbury Pharmacal, Inc., 231 F.3d 1339, 1345-47 (Fed. Cir. 2000). 58 The Court in Eli Lilly quoted 35 U.S.C. § 271(e)(2) and (e)(4), 496 U.S. at 675, as follows: “ ‘(2) It shall\nbe an act of infringement to submit an application under section 505(j) of the Federal Food, Drug, and\nCosmetic Act or described in section 505(b)(2) of such Act for a drug claimed in a patent or the use of\nwhich is claimed in a patent, if the purpose of such submission is to obtain approval under such Act to\nengage in the commercial manufacture, use, or sale of a drug claimed in a patent or the use of which is\nclaimed in a patent before the expiration of such patent. * * *\n**** POSTU-139175-10 54 The function of the paragraphs in question is to define a new (and\nsomewhat artificial) act of infringement for a very limited and\ntechnical purpose . . . .\n496 U.S. at 676 (emphasis added). The Supreme Court went on to explain, with respect to the Hatch-Waxman Act regime\nof exempting the use of patented inventions to develop generic drugs from infringement\nsuits then creating an artificial act of infringement, as follows: This scheme will not work, of course, if the holder of the patent\npertaining to the pioneer drug is disabled from establishing in court\nthat there has been an act of infringement. And that was precisely\nthe disability that the new [35 U.S.C.] § 271(e)(1) imposed with\nregard to use of his patented invention only for the purpose of\nobtaining premarketing approval. Thus, an act of infringement had\nto be created for these ANDA[s] . . . . That is what is achieved by\n§ 271(e)(2)-the creation of a highly artificial act of infringement that\nconsists of submitting an ANDA . . . Not only is the defined act of\ninfringement artificial, so are the specified consequences, as set\nforth in subsection (e)(4). Monetary damages are permitted only if\nthere has been “commercial manufacture, use, or sale.” 35 U.S.C.\n§ 271(e)(4)(C)."
    },
    {
      "id": "legal-advice_43__24",
      "chunk_id": "24",
      "content": "Not only is the defined act of\ninfringement artificial, so are the specified consequences, as set\nforth in subsection (e)(4). Monetary damages are permitted only if\nthere has been “commercial manufacture, use, or sale.” 35 U.S.C.\n§ 271(e)(4)(C). Quite obviously, the purpose of subsections (e)(2)\nand (e)(4) is to enable the judicial adjudication upon which the\nANDA . . . schemes depend. It is wholly to be expected, therefore, ‘(4) For an act of infringement described in paragraph (2)‘(A) the court shall order the effective date of any approval of the drug involved in the infringement to be a\ndate which is not earlier than the date of the expiration of the patent which has been in-fringed,\n‘(B) injunctive relief may be granted against an infringer to prevent the commercial manufacture, use, or\nsale of an approved drug,\nand\n‘(C) damages or other monetary relief may be awarded against an infringer only if there has been\ncommercial manufacture, use, or sale of an approved drug. ‘The remedies prescribed by subparagraphs (A), (B), and (C) are the only remedies which may be\ngranted by a court for an act of infringement described in paragraph, except that a court may award\nattorney fees under section 285.” 35 U.S.C. §§ 271(e)(2), (4).\n496 U.S. at 675-676 (emphasis added). POSTU-139175-10 55 that these provisions would apply only to applications under the\nsections establishing those schemes . . . . Eli Lilly & Co., 496 U.S. at 678 (footnote omitted)(emphasis added). By this exemption/infringement scheme/regime, the Hatch-Waxman Act intended to\naccelerate the vetting of the validity of listed patents to accelerate the approval of\ngeneric drugs. See Shashank Upadhye, Mechanics of Orange Book Patent\nCertifications and Notice Letters, Generic Pharmaceutical Patent and FDA Law, §10:15,\nGenpharma (2011)(“The crux of the Hatch Waxman generic drug approval process\nrevolves around vetting out patent issues vis-à-vis the Paragraph IV Certification.”). To carryout this regulatory scheme, the sponsor (applicant) of the ANDA is required to\ninclude in the ANDA:\n[A] certification, in the opinion of the applicant and to the best of his\nknowledge, with respect to each patent which claims the listed drug\nreferred to in clause (i) or which claims a use for such listed drug\nfor which the applicant is seeking approval under this subsection\nand for which information is required to be filed under subsection\n(b) or (c) of this section-(I) that such patent information has not been filed,\n(II) that such patent has expired,\n(III) of the date on which such patent will expire, or\n(IV) that such patent is invalid or will not be infringed by the\nmanufacture, use, or sale of the new drug for which the\napplication is submitted. 21 USC § 355 (j)(2)(A)(vii). The last certification is referred to as a paragraph IV certification. See 21 C.F.R.\n§ 314.95 (2009) (regulation addressing certification requirement). For an ANDA with a\nparagraph IV certification, the sponsor (applicant) must send notices within 20 days of\nbeing notified by the FDA that the ANDA is accepted for filing59 to the NDA holder for\nthe referenced drug60 and all patentees of record for the listed patents61 that the\n59"
    },
    {
      "id": "legal-advice_43__25",
      "chunk_id": "25",
      "content": "For an ANDA with a\nparagraph IV certification, the sponsor (applicant) must send notices within 20 days of\nbeing notified by the FDA that the ANDA is accepted for filing59 to the NDA holder for\nthe referenced drug60 and all patentees of record for the listed patents61 that the\n59 Notification by the FDA that an ANDA is accepted for filing does not mean it is approved by the FDA,\njust that the application appears to be sufficient to consider on the merits. 60 The FDA-approved NDA drug that the generic drug “mimics” is, for convenience, referred to herein as\nthe “referenced drug;” but, that term is not necessarily used in the technical sense of the term “reference\nlisted drug” or “RLD.” The Orange Book, Orange Book Publications, U.S. Food and Drug Administration,\nhttp://www.accessdata.fda.gov/scripts/Cder/ob/eclink.cfm (Annual ed., last visited on May 25, 2011), POSTU-139175-10 56 applicant has filed an ANDA with a paragraph IV certification. 21 U.S.C.\n§ 355(j)(2)(B)(i)-(iii)(2010). The notification must set forth the reasons the applicant\ncontends the patents are invalid and/or not infringed. 21 U.S.C. § 355(j)(2)(B)(iv)(2010). Specifically, the notice must include, pursuant to 21 C.F.R. § 314.95(c)(6)(2009):\n(6) A detailed statement of the factual and legal basis of the\napplicant's opinion that the patent is not valid, unenforceable, or will\nnot be infringed. The applicant shall include in the detailed\nstatement:\n(i) For each claim of a patent alleged not to be infringed, a\nfull and detailed explanation of why the claim is not infringed. (ii) For each claim of a patent alleged to be invalid or\nunenforceable, a full and detailed explanation of the grounds\nsupporting the allegation. If neither the patents holders nor the NDA holder bring an infringement suit against the\nANDA sponsor (applicant) with a Paragraph IV Certification within forty five days from\nthe day after receipt of the notice, and if the application otherwise meets with approval,\nthe FDA may approve the generic drug. If suit is brought within said forty-five day\nperiod, the ANDA will be subject to a thirty-month stay unless the patent is earlier found\nto be invalid or not infringed, as explained in Natalie Pous, Shifting the Balance\nBetween Branded and Generic Pharmaceutical Companies: Amendments to HatchWaxman Past, Present, And Future, 19 Fed. Cir. B.J. 301 (2009):\n[i]f the patent owner chooses to bring an infringement suit against\nthe ANDA applicant within forty-five days, the FDA is prohibited\nfrom approving the generic version of the drug for thirty months\n(“thirty-month stay”) or until the patent is found to be invalid or not\ninfringed. If, before the thirty-month stay expires, the court holds\nthat the patent is invalid or would not be infringed by the ANDA\napplication, then the FDA will approve the ANDA upon that\ndecision. Otherwise, “the FDA will not approve the ANDA until the\n[original] patent expires.”"
    },
    {
      "id": "legal-advice_43__26",
      "chunk_id": "26",
      "content": "If, before the thirty-month stay expires, the court holds\nthat the patent is invalid or would not be infringed by the ANDA\napplication, then the FDA will approve the ANDA upon that\ndecision. Otherwise, “the FDA will not approve the ANDA until the\n[original] patent expires.” 19 Fed. Cir. B.J. at 305-306 (footnotes omitted)\nIntroduction § 1.4, states “[a] reference listed drug (21 CFR 314.94(a)(3)) means the listed drug identified\nby FDA . . . ” (emphasis added) Section 1.4 further explains that “[b]y designating a single reference\nlisted drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes\nto avoid possible significant variations among generic drugs and their brand name counterpart. Such\nvariations could result if generic drugs were compared to different reference listed drugs.” However,\nSection 1.4 explains that, in certain circumstances, another listed drug can become an additional\nreferenced drug and, in some circumstances, two listed drugs can both be reference listed drugs, with\nspecific terminology used for the reference listed drugs addressed in Section 1.4. 61 The patents in the Orange Book for the referenced drugs are referred to herein as “listed.” POSTU-139175-10 57 However, if the patent litigation is not resolved during the thirty-month stay, the FDA will\napprove the ANDA if all other requirements are met, but the generic drug company\nproceeds at its own risk, as explained below. If the generic applicant makes a paragraph IV certification and suit\nis brought within forty-five days, final approval is stayed for thirty\nmonths or until a court decision of validity and non-infringement. If\nthe case is resolved in favor of the patent owner, the court must\norder that final approval take effect no earlier than patent expiry. If\nthe litigation is ongoing at the conclusion of the thirty months, FDA\nmust approve the ANDA if it is otherwise approvable, and the\ngeneric applicant may market its product. In this case,\nhowever, [the ANDA holder] risks damages for patent infringement\nif it later loses the lawsuit. The patent owner may bring a patent\ninfringement suit later, but if it brings suit after the forty-five day\nnotice period, there is no thirty-month stay of generic approval. Krista Hessler Carver, Jeffrey Elikan and Erika Lietzan, An Unofficial Legislative History\nof the Biologics Price Competition and Innovation Act of 2009, 65 Food & Drug L.J. 671,\n678 (2010)(footnotes omitted). To counter the burden of being sued for infringement, the Hatch-Waxman Act provides\nan incentive for the generic company to expose itself to an infringement suit in order to\nbring a generic drug to market, a 180-day period of exclusivity for the generic product in\nthe market. The fundamental goal behind 180-day exclusivity was to provide an\nincentive for generic drug applicants to challenge innovator patents,\nand the core of the concept--as it has been applied by the Food\nand Drug Administration (FDA) and the courts--is that the first\ngeneric drug applicant to challenge an innovator's patent is entitled\nto six months of exclusivity against subsequent patent challengers\nfor the same innovator drug. 180-day exclusivity is governed by\nsections 505(j)(5)(B)(iv) and 505(j)(5)(D) of the FDCA."
    },
    {
      "id": "legal-advice_43__27",
      "chunk_id": "27",
      "content": "180-day exclusivity is governed by\nsections 505(j)(5)(B)(iv) and 505(j)(5)(D) of the FDCA. David E. Korn, Erika Lietzan and Shaw W. Scott, A New History and Discussion of 180Day Exclusivity, 64 Food & Drug L.J. 335 at 335 (2009)(emphasis added). The first to file62 a substantially complete ANDA with a paragraph IV certification\n(subject to other requirements, including the applicable exclusivity periods granted to\nthe FDA-approved NDA63) obtains 180 days of exclusivity over other generic drug\n62 There can be more than one first filer if multiple ANDAs are submitted on the same day. See Center\nfor Drug Evaluation and Research, Food and Drug Administration, U.S. Dept. of Health and Human\nServices, Guidance for Industry, 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same\nDay (July, 2003). 63 21 U.S.C. § 355(j)(5)(B)(2010) provides that approvals can be made effective subject to conditions;\nhowever, the statute also provides that the FDA can send tentative approval letters. The FDA’s POSTU-139175-10 58 ANDA filings.64 21 U.S.C. § 355(j)(5)(B)(iv)(2010). The 180 days of exclusivity is\nvaluable to the generic drug producer. The article by David E. Korn, Erika Lietzan and\nShaw W. Scott (cited above) addresses multiple views of the value of the 180-day\nexclusivity,65 with one view stated as follows: 66 interpretation of the definition of tentative approval letters may limit the use of tentative approval letters to\nsituations where the exclusivity period is relative to the NDA-approved drugs (e.g., new innovative\npediatric drug exclusivity or new innovative drug for rare condition exclusivity - periods of exclusivity that\ncan apply after the patents expire and are cross referenced in the statute provision defining tentative\napproval), not the 180-day exclusivity of the first applicant. Tentative Approval. If a generic drug product is ready for approval before the\nexpiration of any patents or exclusivities accorded to the reference listed drug\nproduct, FDA issues a tentative approval letter to the applicant. The tentative\napproval letter details the circumstances associated with the tentative approval. FDA delays final approval of the generic drug product until all patent or\nexclusivity issues have been resolved. A tentative approval does not allow the\napplicant to market the generic drug product. U.S. Food and Drug Administration, Glossary of Terms,\nwww.fda.gov/Drugs/InformationOnDrugs/ucm079436.htm (last visited on 8/16/2011)(emphasis added). The article by Erika Lietzan and David E. Korn, Issues in the Interpretation of 180-Day Exclusivity, 62\nFood & Drug L.J. 49, 50 (2007) may interpret the language in 21 U.S.C. § 505(j)(5)(B)(iv) as barring FDA\napproval (even tentative) if a prior ANDA filer may be a first applicant entitled to 180-days of exclusivity. See Teva Pharmaceutical Industries v. Crawford, FDA, 410 F.3d 51, 54 (D.C. Cir. 2005)(“The means the\nCongress ‘deemed appropriate, and prescribed’ to give generic drug makers an incentive to challenge\nbrand-drug patents is unambiguous: The FDA may not approve a second or later ANDA containing a\nparagraph (IV) certification until 180 days after the first filer with such a certification begins commercially\nmarketing the drug . . . .”) . 64 The exclusivity does not extend to the drugs known as authorized generics (AG), “generics” that are\nmarketed and sold pursuant to a license from an NDA holder."
    },
    {
      "id": "legal-advice_43__28",
      "chunk_id": "28",
      "content": "64 The exclusivity does not extend to the drugs known as authorized generics (AG), “generics” that are\nmarketed and sold pursuant to a license from an NDA holder. The Federal Trade Commission Study,\n“Authorized Generics; An Interim Report, 2009 WL 1847678 (F.T.C.), June 2009 found that “[b]etween\nFY2004-FY2008, 76 final patent settlement agreements were with first-filer generics. About one-quarter\n(20 out of 76) of those patent settlements involved (1) an explicit agreement by the brand not to launch an\nAG to compete against the first filer, combined with (2) an agreement by the first-filer generic to defer its\nentry past the settlement date by, on average, 34.7 months. With regard to these twenty settlements,\nbranded sales of the affected products ranged from $12.6 million to $5.3 billion, with an average market\nsize of $917 million and a median market size of $514 million. Five of the settlements covered products\nwith annual sales of $1 billion, $1.1 billion, $2.1 billion, $2.5 billion, and $5.3 billion.” See Asim Varma,\nSon B. Nguyen and Justin P. Hedge, The FTC Reports on Follow-On Biologics and Authorized Generics:\nApplying Lessons from Hatch-Waxman to Promote Competition, Antitrust 41, 42 (Fall, 2009) (addressing\ntwo reports issued by FTC). See also “Pay-For-Delay Settlements, Authorized Generics, and Follow-on\nBiologics: Thoughts on the [sic] How Competition law Can Best Protect Consumer Welfare in the\nPharmaceutical Context,” by J. Thomas Rosch, Federal Trade Commission, 2009 WL 4047975,\nNovember 19, 2009 (presented at the World Generic Medicine Congress by an F.T.C. Commissioner). 65 64 Food & Drug L.J. at 383-385. 66 Id. at 384 (footnotes omitted) (emphasis added). POSTU-139175-10 59 In light of the average selling price of the first generic drug in the\nmarket, some have estimated that a first filer awarded 180-day\nexclusivity could, in fact, “expect a 1,000 percent return on\ninvestment.” In addition, first filers, by launching their generic drugs\nin the absence of other generic competitors, may have the\nadvantage of being able to enter into long-term supply contracts\nwith pharmacies retailing their products. The 180-day exclusivity is transferable in certain circumstances. See Mary W. Bourke\nand Edward Danberg, Current Trends in Hatch-Waxman Patent Litigation: A System\nStill in Flux, Practicing Law Institute 878 PLI/Pat 939, § I.C.5 (2006) (“exclusivity may be\ntransferred separately from the ANDA [quoting Mylan Pharm. Inc. v. Shalala, 81 F.\nSupp.2d 30, 47-48 (D.D.C. 2000)] that ‘[e]xclusivity periods are a transferable\ncommodity which can be waived in favor of another generic manufacturer for a\nsubstantial price.’”)(emphasis added). 67 However, the 180-day exclusivity can be\nforfeited in certain circumstances. The court decision trigger for forfeiture states that 180-day exclusivity is\nforfeited if the applicant fails to market 75 days after, as to each patent at\nissue, “a court enters a final decision from which no appeal (other than a\npetition to the Supreme Court for a writ of certiorari) has been or can be\ntaken that the patent is invalid or not infringed”-- unless 75 days have not\nelapsed since the ANDA approval was effective and 30 months have not\nelapsed since the ANDA was submitted."
    },
    {
      "id": "legal-advice_43__29",
      "chunk_id": "29",
      "content": "Put another way, forfeiture\noccurs if: 1) every patent as to which the first applicant filed a paragraph\nIV certification has been declared invalid or not infringed in a final court\ndecision, and 75 days have elapsed since the last such decision; and 2)\n30 months have elapsed since the ANDA was submitted or FDA has\ngranted final approval to the ANDA, and 75 days have elapsed since that\napproval was effective. David E. Korn, Erika Lietzan and Shaw W. Scott, A New History and Discussion of 180Day Exclusivity, 64 Food & Drug L.J. 335 at 362 67 See also David E. Korn, Erika Lietzan and Shaw W. Scott, A New History and Discussion of 180-Day\nExclusivity, 64 Food & Drug L.J. 335 at 348 (“After a triggering event occurred, the first generic would be\npermitted to waive its rights in favor of another company. FDA noted that waiver can be particularly useful\nwhen a subsequent generic wins its patent suit with the innovator before the first generic's suit goes to\ntrial. Prior to the triggering event, however, the first generic could not waive its exclusivity rights. It could\nrelinquish its rights--waive its exclusivity entirely--permitting FDA to approve all subsequent ANDAs, but it\ncould not sell the exclusivity term to a particular generic manufacturer. FDA withdrew its proposed\nregulations in 2002, but confirmed this position two years later in response to a Pfizer citizen petition.”). POSTU-139175-10 60 An ANDA, itself, can be transferred on a stand-alone basis from the original sponsor\n(entity that submitted the application for the ANDA) or current ANDA holder to another,68\nprovided the requirements of 21 C.F.R. § 314.72 are met. The transferee is called the\n“holder” of the ANDA. Many cases describe one or more aspects of the regulatory regime summarized above. See Schering-Plough Corporation v. FTC, 402 F. 3d 1056 (11th Cir. 2005);69 Mylan\nPharmaceuticals, Inc. vs. United States Food and Drug Administration, 454 F. 3d 270\n(4th Cir. 2006);70 Teva Pharmaceuticals v. Leavitt, HHS, 548 F. 3d 103 (D. C. Cir.\n68 “An applicant may transfer ownership of its application. At the time of transfer the new and former\nowners are required to submit information to the Food and Drug Administration . . . . ” 21 C.F.R .\n§ 314.72(a).\n69 “Previously, applications for FDA approval proceeded under a new drug application (“NDA”). 21 U.S.C.\n§ 355(b). This cumbersome and involved process required each applicant to submit safety and efficacy\nstudies, even if it duplicated previous studies done on identical drugs with the same ingredients. In 1984,\nCongress passed [the] Drug Price Competition and Patent Term Restoration Act (the “Hatch-Waxman\nAct”), Pub. L. No. 98-417, 98 Stat. 1585 (1984). The purpose of the Hatch-Waxman Act was threefold:\n(1) to reduce the average price paid by consumers; (2) preserve the technologies pioneered by the brandname pharmaceutical companies; and (3) create an abbreviated new drug application (“ANDA”) to bring\ngeneric drugs to the market.” 402 F.3d at 1059, n.2. “The ANDA process allows the manufacturers of generic drugs to gain early entry into the market."
    },
    {
      "id": "legal-advice_43__30",
      "chunk_id": "30",
      "content": "402 F.3d at 1059, n.2. “The ANDA process allows the manufacturers of generic drugs to gain early entry into the market. HatchWaxman's truncated procedure avoids the duplication of expensive safety and efficacy studies, so long as\nthe generic manufacturer proves that its drug is bioequivalent to the already-approved brandname/pioneer drug. As part of the application process, the generic applicant must certify that the relevant\npatent(s) on the brand-name drug are either invalid or will not be infringed. This is commonly known as a\n’Paragraph IV certification.’ The patent holder is then notified of the ANDA, and if the patent holder sues\nfor infringement within forty-five days of receiving the notice, the FDA automatically institutes a thirtymonth delay on the generic manufacturer's ANDA approval. See 21 U.S.C. 355(j)(5)(B)(iii) .” Id.\n70 “The Hatch-Waxman scheme distinguishes between New Drug Applications (NDAs) and Abbreviated\nNew Drug Applications (ANDAs). To seek FDA approval for a pioneer drug, the manufacturer must file a\ncomplete NDA. Such a filing must ‘provide the FDA with a listing of all patents that claim the approved\ndrug or a method of using the drug.’ aaiPharma Inc., 296 F.3d at 230. The NDA must also set forth data\nestablishing that the drug is safe and effective. See 21 U.S.C. § 355(b). Later, a company that makes a\ngeneric drug that is biologically equivalent to the pioneer drug may seek FDA approval for the drug by\nfiling an ANDA. The ANDA relies on the pioneer drug's safety and effectiveness studies. See 21 U.S.C.\n§ 355(j); aaiPharma Inc., 296 F.3d at 231.” 454 F.3d at 272. “The ANDA must contain a certification as to whether the proposed generic drug would infringe the patent\nprotecting the pioneer drug, and if not, why not. Pertinent here is the fourth of the statute's four\ncertification options (the paragraph IV option), allowing the ANDA applicant to certify that the pioneer\ndrug's patent is ’invalid or will not be infringed by the manufacture, use, or sale of the new drug for which\nthe application is submitted.’ 21 U.S.C. § 355(j)(2)(A)(vii)(IV). Thus, ’an ANDA applicant making a\nparagraph IV certification intends to market its product before the relevant patents have expired.’\naaiPharma Inc., 296 F.3d at 232. The patent holder and the NDA holder (which usually are the same\ncompany, the pioneer drug maker) are entitled to notice that a paragraph IV ANDA has been filed. If,\nupon receiving such notice, the patent holder sues the applicant for patent infringement within 45 days,\nthe FDA must stay a decision on whether to approve the ANDA for 30 months (unless the patent expires\nor a court holds that it is invalid or not infringed during that time). 21 U.S.C. § 355(j)(5)(B)(iii).“ Id. POSTU-139175-10 61 2008).71 See also In the Matter of 180-Day Generic Drug Exclusivity for Abbreviated\nNew Drug Applications, Docket No. 85N-0214, Comment of the Staff of the Bureau of\nCompetition and of Policy Planning of the Federal Trade Commissioner, November 4,\n1999.72 Once an ANDA is approved, the holder of the ANDA is still subject to numerous FDA\nrequirements in order to retain the right to market and sell the approved generic drug."
    },
    {
      "id": "legal-advice_43__31",
      "chunk_id": "31",
      "content": "Once an ANDA is approved, the holder of the ANDA is still subject to numerous FDA\nrequirements in order to retain the right to market and sell the approved generic drug. If\nthe requirements are not met, the ANDA will no longer be effective. 73\nSome of the FDA-imposed requirements to maintain the ANDA are in 21 C.F.R.\n§ 314.80 (2009), Postmarketing Reporting of Adverse Drug Experiences,74 which\nrequires that the ANDA applicant/holder75 shall, inter alia:\n71 “To start the process, the ANDA applicant must certify-for each patent claiming a drug for which the\napplicant is seeking approval-under one of four paragraphs that (I) patent information has not been filed;\n(II) the patent has expired; (III) the patent will expire on a specified date; or (IV) the patent is invalid or will\nnot be infringed by the manufacture, use, or sale of the new drug for which the application is submitted. Id. § 355(j)(2)(A)(vii). The first drug manufacturer to file an approved ANDA, containing a paragraph IV\ncertification, is rewarded with a 180-day period of marketing exclusivity for the manufacturer's generic\nversion of the drug. Id. § 355(j)(5)(B)(iv). Marketing exclusivity is valuable, designed to compensate\nmanufacturers for research and development costs as well as the risk of litigation from patent holders. See 35 U.S.C. § 271(e)(2)(A) (stating a generic drug company certifying under paragraph IV commits an\nact of infringement for which the brand-name drug's patent holder can sue).” 548 F.3d at 104.\n72 “In 1984, Congress enacted the Hatch-Waxman Act to establish a streamlined approval process for the\nFDA to use in approving generic versions of previously approved branded drugs. The Hatch-Waxman Act specifies in detail the required contents of an ANDA. * * *\n* * * [I]f an ANDA applicant files a paragraph IV certification, the Hatch-Waxman Act requires the\napplicant to provide the patent holder with notice of that certification and provides the patent holder with a\n45-day window, during which it may bring suit against the applicant. If patent litigation is initiated during\nthis period, the FDA may not approve the ANDA until the earlier of (1) 30 months from the patent holder’s\nreceipt of the notice (the 30-month stay) or (2) the issuance of a non-appealable court decision finding the\npatent invalid or not infringed. This allows the patent holder time to enforce its patent in court before the\ngeneric competitor is allowed to enter the market.” (footnotes omitted). 73"
    },
    {
      "id": "legal-advice_43__32",
      "chunk_id": "32",
      "content": "This allows the patent holder time to enforce its patent in court before the\ngeneric competitor is allowed to enter the market.” (footnotes omitted). 73 See generally 21 C.F.R. § 314.150 (describes the instances in which the FDA will withdraw an approval\nof an NDA or an ANDA); See also 21 U.S.C.§ 355(k)(1)(2010) (states, in part, that the applicant must\nmaintain records and reports of data relating to the clinical experience and other data or information\nreceived or obtained by the applicant with respect to such drug, and that these records may be reviewed\nto determine if there are grounds to invoke 21 U.S.C. § 355(e)); and 21 U.S.C. § 355(e) (details the\ngrounds for withdrawing the approval of either an NDA or ANDA, including scientific data showing the\ndrug is unsafe for use under the conditions of use of which the application was approved, that the\napplication contains untrue statements of material fact, that the applicant has failed to maintain a system\nof required records, or that the methods used in or the facilities and controls used for the manufacture,\nprocessing and packing of such drug are inadequate to assure and preserve its identity, strength, quality\nand purity or the labeling of such drug is false or misleading). 74 “Except as provided in paragraph (b) of this section, each applicant having an approved abbreviated\nnew drug application under § 314.94 that is effective shall comply with the requirements of § 314.80\nregarding the reporting and recordkeeping of adverse drug experiences. POSTU-139175-10 62 1. “[D]evelop written procedures for the surveillance, receipt, evaluation, and\nreporting of postmarketing adverse drug experiences to FDA.” 21 C.F.R.\n§ 314.80(b)(2009)(emphasis added); 2. “[R]eport each adverse drug experience that is both serious and unexpected,\nwhether foreign or domestic, as soon as possible but in no case later than 15\ncalendar days of initial receipt of the information . . .” 21 C.F.R.\n§ 314.80(c)(1)(i)(2009) (emphasis added); 3. “[P]romptly investigate all adverse drug experiences that are the subject of\nthese postmarketing 15-day Alert reports and shall submit follow-up reports\nwithin 15 calendar days of receipt of new information or as requested by\nFDA.” 21 C.F.R. § 314.80(c)(1)(ii)(2009) (emphasis added); 4. “[R]eport each adverse drug experience not reported under paragraph\n(c)(1)(i) of this section at quarterly intervals, for 3 years from the date of\napproval of the application, and then at annual intervals . . . Upon written\nnotice, FDA may extend or reestablish the requirement that an applicant\nsubmit quarterly reports, or require that the applicant submit reports under\nthis section at different times than those stated.” 21 C.F.R.\n§ 314.80(c)(2)(i)(2009)(emphasis added); and 5. Provide “[a] 15-day Alert report based on information from the scientific\nliterature . . .” 21 C.F.R. § 314.80(d)(1)(2009)(emphasis added). More examples of the FDA-imposed requirements can be found in 21 C.F.R.\n§ 314.81 (2009), Other Postmarketing Reports, which requires the ANDA holder to\nprovide, inter alia:\n1. “Information concerning any incident that causes the drug product or its\nlabeling to be mistaken for, or applied to, another article.” 21 C.F.R.\n§ 314.81(b)(1)(i)(2011)(emphasis added); 2."
    },
    {
      "id": "legal-advice_43__33",
      "chunk_id": "33",
      "content": "More examples of the FDA-imposed requirements can be found in 21 C.F.R.\n§ 314.81 (2009), Other Postmarketing Reports, which requires the ANDA holder to\nprovide, inter alia:\n1. “Information concerning any incident that causes the drug product or its\nlabeling to be mistaken for, or applied to, another article.” 21 C.F.R.\n§ 314.81(b)(1)(i)(2011)(emphasis added); 2. “Information concerning any bacteriological contamination, or any significant\nchemical, physical, or other change or deterioration in the distributed drug\nproduct, or any failure of one or more distributed batches of the drug product * * * “Each applicant shall make the reports required under § 314.81 and section 505(k) of the act for\neach of its approved abbreviated applications. “ 21 C.F.R. § 314.98(a) and (c) (emphasis added). 75 21 C.F.R. § 314.80(c)(1)(iii)(2009) clarifies that the requirements “shall also apply to any person other\nthan the applicant (nonapplicant) whose name appears on the label of an approved drug product as a\nmanufacturer, packer, or distributor.” This summary does not address to what extent, if any, the ANDA\napplicant also has continuing responsibilities after it has sold or otherwise transferred its ANDA to another\nunrelated party. POSTU-139175-10 63 to meet the specification established for it in the application.” 21 C.F.R.\n§ 314.81(b)(1)(ii)(2010)(emphasis added);\n3. An annual report that must include, inter alia:\na. “A brief summary of significant new information from the previous year that\nmight affect the safety, effectiveness, or labeling of the drug product. The\nreport is also required to contain a brief description of actions the applicant\nhas taken or intends to take as a result of this new information, for\nexample, submit a labeling supplement, add a warning to the labeling, or\ninitiate a new study.” 21 C.F.R. § 314.81(b)(2)(i)(2010)(emphasis added). b. “Information about the quantity of the drug product distributed under the\napproved application . . . “ 21 C.F.R. § 314.81(b)(2)(ii)(a)(2010)(emphasis\nadded); 4. Reports are also required on, inter alia:\na. “Currently used professional labeling, patient brochures or package inserts\n(if any), and a representative sample of the package labels.” 21 C.F.R.\n§ 314.81(b)(2)(iii)(a)(2010)(emphasis added). b. “[C]hanges in labeling that have been made since the last report listed by\ndate in the order in which they were implemented, or if no changes, a\nstatement of that fact.” 21 C.F.R. § 314.81(b)(2)(iii) (c)(2010)(emphasis\nadded); 5. Numerous reporting requirements on clinical and other studies; and 6. Requirements to “submit specimens of mailing pieces and any other labeling\nor advertising devised for promotion of the drug product at the time of initial\ndissemination of the labeling and at the time of initial publication of the\nadvertisement for a prescription drug product. “ 21 C.F.R.\n§ 314.81(b)(3)(i)(2010)(emphasis added). See Karen L. Drake, FDA Regulation of the Advertising and Promotion of Prescription\nDrugs, Biologics, and Medical Devices, FDA Regulatory Affairs, A Guide for Prescription\nDrugs, Medical Devices and Biologics, 267-287 (Douglas J. Pisano and David S.\nMantus, eds., 2nd Ed., 2008). The FDA approval letter for an ANDA may subject the approval to additional\nrequirements that must be met to maintain the ANDA, such as specific procedures for\nmanufacturing.76\n76 See http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (search by ANDA number to find\napproval letters that are online) (last visited on June 2, 2011). POSTU-139175-10 64"
    },
    {
      "id": "legal-advice_43__34",
      "chunk_id": "34",
      "content": "The FDA approval letter for an ANDA may subject the approval to additional\nrequirements that must be met to maintain the ANDA, such as specific procedures for\nmanufacturing.76\n76 See http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (search by ANDA number to find\napproval letters that are online) (last visited on June 2, 2011). POSTU-139175-10 64 In addition, the ANDA holder must follow the FDA’s rules on good manufacturing\npractices and allow FDA inspections of the manufacturing facilities. See Bob Buckley\nand Robert Blanks, Overview of the GxPs for the Regulatory Professional, FDA\nRegulatory Affairs: A Guide for Prescription Drugs, Medical Devices and Biologics, 213266. (Douglas J. Pisano and David S. Mantus, eds., 2nd Ed., 2008) (Summarizing\nnumerous requirements, with citations)."
    }
  ]
}